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ABSTRACT 
 
BRITTANY LYNNE MORTENSEN: Mechanisms of Francisella tularensis virulence as 
revealed by RipA and IclR  
(Under the direction of Thomas H. Kawula) 
 
 F. tularensis is a Gram-negative coccobacillus that is the etiologic agent of the 
zoonotic disease tularemia. With a low infectious dose via the inhalational route and the 
ability to cause a potentially severe disease in humans, F. tularensis is a very successful 
pathogen.  While it is known that F. tularensis depends on intracellular replication and 
immune suppression of the host, little is known about the specific mechanisms of virulence. 
Using a screen to identify genes required for intracellular replication, we identified a locus 
FTL_1914 which was subsequently named ripA. A mutant containing a deletion of ripA 
(LVS∆ripA) escaped the phagosome; however, it failed to replicate intracellularly in the 
cytoplasm of macrophages and epithelial cells and was attenuated in a mouse model of 
pulmonary tularemia. Later studies showed that RipA is a conserved cytoplasmic membrane 
protein with similarity to hypothetical proteins of unknown function in a few randomly-
distributed bacterial strains. Therefore, the function of RipA is not known. Investigation into 
protein-protein interactions involving RipA identified a putative RipA-interacting protein 
termed IclR (FTL_1364). In studies to determine the biological relevance of the RipA-IclR 
interaction, we analyzed the role of IclR to the virulence of F. tularensis. Deletion of iclR in 
F. tularensis LVS and Schu S4 suggested that unlike the non-pathogenic F. novicida, IclR 
was not required for virulence of human-virulent strains of F. tularensis and therefore, likely 
not required for RipA function. Further studies into RipA function using LVS∆ripA led to a 
 iii 
 
greater understanding of innate immune signaling pathways that are being suppressed by F. 
tularensis. Finally, biochemical determination of the unique topology of RipA and 
identification of functional domains revealed new insights into a potentially new family in 
proteins conserved throughout Prokaryotes. Together, not only do these studies provide 
general characterization of two F. tularensis proteins, they help elucidate mechanisms of 
virulence utilized by the highly pathogenic F. tularensis. 
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FRANCISELLA CLASSIFICATION AND EPIDEMIOLOGY 
 Francisella tularensis is a Gram-negative, coccobacillus belonging to the family 
Francisellaceae of the γ-Proteobacteria. Francisellaceae are found throughout the 
environment and commonly isolated from marine and fresh water (30, 37, 135); however, the 
environmental reservoir is not known. Additionally, Francisellaceae have been isolated from 
a wide-range of animal species. The most common mammalian hosts are lagomorphs such as 
rabbits, but Francisellaceae have been isolated from over 500 other species including rodents 
(188), birds (211), cats (238), dogs (125, 126), sheep and oxen (13), fish (214), and even 
crayfish (8). F. tularensis is also frequently recovered from arthropod vectors, mainly ticks 
(188), flies (155), and mosquitoes (86). Certain species within Francisellaceae have been 
reported to infect amoeba, including Acanthamoeba castellani (1, 85, 164, 277) and 
Hartmannella vermiformis (250) suggesting that amoeba may serve as an environmental 
reservoir; however, F. tularensis has not yet been isolated from amoeba in nature.
 F. tularensis infection in many of the animal hosts, including humans, results in the 
development of the zoonotic disease tularemia. In fact, F. tularensis was first identified as 
Bacterium tularense, the organism causing a disease in ground squirrels in Tulare County, 
California in 1911 (196, 197). Soon after, a febrile disease in humans called “deer-fly fever” 
was reported in Utah (219). Dr. Edward Francis is attributed with the identification and 
naming of Bacterium tularense as the agent causing “deer-fly fever” in the Utah patients 
(105, 106), and in 1947 the organism was renamed to Francisella tularensis in recognition of 
his contributions (215, 221). F. noatunensis (203, 204), F. philomiragia (214), and F. 
piscicida (216) species are now known as common fish pathogens, and F. philomiragia has 
caused disease in humans in a few isolated cases with immune-compromised patients or 
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near-drowning victims (107, 262, 285).  The diverse host range and geographic distribution 
of Franciselleaceae reflects the success of the organism to adapt to many environments, 
including humans. Based on the ability to infect and cause disease in so many hosts, there is 
a repertoire of animal models, including non-human primates (287), mice (27), rabbits (27), 
guinea pigs (27), rats (144, 233, 289), zebrafish (279), A. castellani (1), H. vermiformis 
(250), and Drosophila melanogaster (280), that have been used for studying the pathogenesis 
in F. tularensis infections. 
 There are three main subspecies of F. tularensis, the species that causes tularemia in 
humans: tularensis, holarctica, and mediasiastica. F. tularensis subspecies tularensis has 
only been reported in North America and is considered the most highly infectious subspecies 
for humans (269). Subspecies tularensis is also known as Type A and the primary strain used 
in research is the Schu S4 strain, which requires biosafety level 3 conditions to handle in the 
laboratory. F. tularensis subspecies holarctica is found throughout the northern hemisphere, 
and while holarctica still infects humans, this subspecies has a higher infectious dose (<1000 
organisms) and usually causes a less severe form of tularemia (269). Nonetheless, subspecies 
holarctica is a source of significant endemic disease in European countries (269). Subspecies 
holarctica was also used to generate the live vaccine strain (LVS) which is one of the 
frequently used strains in laboratories due to the ability to use this strain in under biosafety 
level 2 conditions and retained virulence for mice (269). F. tularensis subspecies 
mediasiatica has been associated with several reports of tularemia in Asia (152); however, 
not much is known about this subspecies. Finally, F. novicida is a commonly-studied species 
of Francisella due to the high genetic similarity to tularensis species and the ability to cause 
disease in mouse models of tularemia. Generally, F. novicida is considered non-pathogenic 
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for humans; however, it has been reported to cause disease, predominantly in immune-
compromised patients (29, 32, 58, 94, 135, 165, 286). The Utah 112 (U112) strain, which 
was isolated from a water sample in Utah in 1955 (161), is a frequently-used laboratory strain 
for F. novicida. Within the field, some consider F. novicida as a subspecies of F. tularensis; 
however, based on divergence realized by whole genome single-nucleotide polymorphism 
analysis as well as differences in virulence and in at least 11 metabolic processes, novicida is 
considered a separate species by others (143, 147, 152, 162, 163). Nevertheless, due to 
journal policies and the current classification debate in the field (45, 147), chapters 2-4 refer 
to F. novicida as F. tularensis subspecies novicida. 
 In humans, tularemia is manifested in several different forms depending on the route 
of transmission of F. tularensis. General symptoms can include fever, headache, chills, joint 
pain, muscle aches, cough, and diarrhea, which begin to appear usually 3-5 days post 
infection (252, 253). Regardless of the route of inoculation, inflammation and swelling of the 
lymph nodes is also typical (269). The most common transmission route is contact with F. 
tularensis through the skin either through bites from arthropod vectors or handling 
contaminated animals, tissues or indirectly through items such as tools or bedding (269).  
There have been multiple cases of tularemia resulting from scratches or bites from house 
pets, commonly cats (205, 255). Dermal contact results in the ulceroglandular form of 
tularemia and the characteristic formation of a lesion at the site of infection (269). 
Transmission via the eye is rare but results in the oculoglandular form of tularemia 
characterized by conjunctivitis and occasionally other complications (269). Ingestion of F. 
tularensis in contaminated food or water results in oropharyngeal tularemia characterized by 
pharyngitis and ulcerative-exudative stomatitis (269). Typhoidal tularemia is the term given 
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when the source of infection is not known (269). The most severe form of tularemia is 
pneumonic tularemia that can be a result of complications from another form of tularemia or 
from inhalation of aerosolized bacteria. Often aerosols are generated by disruption of 
materials such as hay, soil, or grass contaminated with F. tularensis and therefore farmers 
and lawncare workers are often infected in this way (269). A famous set of cases in the 
United States occurred in Martha’s Vineyard where multiple lawn care workers were 
diagnosed with pneumonic tularemia (95, 273). There have also been at least two cases of 
pneumonic tularemia resulting from transmission by dogs (241, 263). Historically, lab 
workers were infected via inhalation, although these incidences have decreased due to 
increased biosafety in handling the organism. Surprisingly, there is no evidence that F. 
tularensis is transmitted human to human (269). 
 F. tularensis subspecies tularensis has a very low infectious dose via the inhalational 
route, with as few as 10 organisms sufficient to cause disease (252, 253), and pneumonic 
tularemia has a mortality rate as high as 60% if left untreated (80). Infection can be 
controlled with prompt antibiotic treatment, and there is partial protection by previous 
vaccination using LVS (80). Due to the lack of knowledge on why LVS is attenuated, only 
being partially protective as a vaccine, and the inability to vaccinate immune-compromised 
individuals with a live strain, LVS is not licensed in the United States. The preferred 
antibiotics for treating tularemia patients are streptomycin or gentamicin, though alternative 
antibiotics can be used such as doxycycline, chloramphenicol, or ciprofloxacin (80). During 
the Cold War, several countries, including the former Soviet Union and the United States, 
stockpiled antibiotic-resistant strains of F. tularensis (5, 217, 254). This fact combined with 
the ease of aerosolization, the low infectious dose via the inhalational route, and the high 
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mortality rate after pulmonary infection, F. tularensis subspecies tularensis is designated as a 
Select Agent by the Centers for Disease Control (80). 
 
PATHOGENESIS AND INTRACELLULAR LIFECYCLE 
 In a pulmonary infection, once in the lung, F. tularensis travels to the alveolus where 
it infects a number of cell types including macrophages, dendritic cells (DCs), neutrophils, 
and Type II alveolar epithelial cells (21, 36, 129, 130). The distribution of infected cells 
changes over the course of infection and among subspecies (130). F. tularensis has also been 
reported to infect erythrocytes (140), fibroblasts (108), kidney epithelial cells (138), and 
hepatocytes (68), cell types that could presumably be infected in systemic disease. Through 
the use of a uracil biosynthesis mutant (∆pyrF), it has been suggested that intracellular 
replication in non-macrophage cells is sufficient to cause infection (139). There is also 
evidence that F. tularensis undergoes an extracellular phase during an infection (21, 99, 292). 
Overall, the ability to infect and manipulate so many cell types reflects the success of F. 
tularensis as a pathogen.  
 Central to F. tularensis virulence is its ability to replicate to high numbers within the 
cytoplasm of host cells. The ability of the bacteria to reach the cytoplasm is dependent on 
both the opsonization of the bacteria and whether the bacteria can escape the phagosome. 
First, in serum-opsonizing conditions, F. tularensis is taken up by looping phagocytosis 
through interaction with complement receptor C3 and actin microfilaments (60). Other 
receptors that may be involved in macrophage uptake under opsonizing conditions are Fcγ 
receptors, surfactant protein A, class A scavenger receptors, and nucleolin (17, 20, 115, 223, 
258). Under non-opsonizing conditions, bacterial phagocytosis is mediated by the mannose 
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receptor with additional contributions by class A scavenger receptors and nucleolin (20, 115, 
223, 258). After phagocytosis, F. tularensis escapes the phagosome as early as 20 minutes 
post invasion, and by approximately 1 hour, begins replicating within the cytoplasm. The 
kinetics of phagosomal escape depends on opsonization status of the bacteria. when 
compared to non-opsonizing conditions, serum opsonization of bacteria delays phagosomal 
escape and thereby impairs intracellular growth (115).  
 After uptake of bacteria and  prior to phagosomal escape, the phagosome undergoes a 
maturation process in which the phagosome acquires early endosomal markers such as EEA1 
and late endosomal markers such as CD63, LAMP-1, and LAMP-2 (59, 119). Studies using 
lysosomotropic agents revealed that these late-stage phagosomes are not acidified, even by 3 
hours post infection (59). On the other hand, additional studies demonstrated that there is an 
initial, transient acidification as well as acquisition of the vacuolar ATPase that drops by 1 
hour post infection, and escape is delayed if acidification is blocked (57, 102, 247). In 
contrast, another study suggests that phagosomal acidification is not required for phagosomal 
escape or intracellular replication (61). Therefore, the requirement for phagosomal 
acidification for phagosomal escape by the bacteria remains under debate. Once in the 
cytoplasm, F. tularensis can replicate up to several logs by 24 hours post infection (10). At 
this point, some bacteria are located in a membranous vacuole shown to be autophagic 
vacuoles, as is discussed below, and it is not yet clear how bacteria exit host cells to spread 
and infect other host cells. 
The mechanisms by which other cell types take up F. tularensis and the lifecycle 
within these other cell types are not as well understood. Epithelial cells take up both viable 
and nonviable F. tularensis bacteria with similar kinetics, suggesting that there is a bacterial 
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surface ligand required for entry, but the host cell receptors involved are not known (75). 
Entry into epithelial cells also requires actin polymerization, microtubule rearrangement, and 
associated upstream signaling by phosphatidylinositol 3-kinase (PI3K) and tyrosine kinase 
pathways (75). Once inside the epithelial cell, F. tularensis escapes the phagosome to 
replicate within the cytoplasm following the same endocytic pathway and with similar 
kinetics as in the macrophage (75). DCs are thought to engulf F. tularensis via a mechanism 
that is dependent on serum opsonization of bacteria and the DC integrins CR3 and CR4 (28). 
Like DCs, neutrophils also take up F. tularensis in a serum-dependent manner (177, 227). 
After entry, F. tularensis bacteria escape the phagosome to persist in the cytoplasm, though 
no reports demonstrate any intracellular replication in neutrophils (194). In fact, F. tularensis 
has been shown to actively recruit neutrophils to the lung at least in part through the activity 
of matrix metalloproteinase-9, suggesting that neutrophils may provide an additional in vivo 
niche for F. tularensis (186). Finally, both complement-dependent and independent 
mechanisms are involved in uptake into erythrocytes, but nothing else is known about the 
lifecycle of F. tularensis in this cell type (140). We still have much to learn about the life 
cycle of F. tularensis within non-macrophage cell types. 
 As noted above, after approximately 24 hours post infection, F. tularensis can be 
observed within multi-membranous vacuoles termed Francisella-containing vacuoles or 
FCVs (54). The study initially characterizing FCVs showed that these vacuoles are 
juxtanuclear and fused with lysosomes, yet there are intact Schu S4 bacteria within. 
Furthermore, FCVs acquired the protein LC3, accumulated monodansylcadaverine, and 
formation was inhibited by 3-methyladenine, together suggesting that the FCV represents an 
autophagosome. Subsequent studies have expanded on the autophagy concept by showing 
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that FCV formation also occurs with LVS and that other autophagy-associated molecules 
such as cathepsin D, phosphatase and tensin homolog (PTEN), and p53 may have altered 
expression in infected cells (141). Finally, microarray studies at 24 hours post infection 
demonstrated that infection with Schu S4 or U112 results in decreased expression of other 
autophagic response proteins and the autophagy-related PI3K signaling pathway (46, 76). 
This suggests that Francisella may be suppressing and thereby delaying the autophagic 
response to infection; however, it is not known what bacterial effectors may be involved. 
 Related to this, some host cell death is induced by F. tularensis, even with bacteria-
mediated suppression of the process. Several reports have shown that F. tularensis induces 
caspase-3 activation and cell death in macrophages and in vivo using F. novicida, LVS, and 
Type A strains KU49 and KU54 (33, 159, 230, 251, 288). To build on this idea, in two 
studies using F. novicida, it was demonstrated that caspase-3 activation and cell death are 
downregulated at early time points as a result of activation of Ras signaling pathways and 
that although there is eventually upregulation of caspase-3, apoptosis is delayed further, 
potentially as a result of anti-apoptotic signaling (6, 251). Therefore, although apoptotic 
pathways are eventually activated, the delayed kinetics suggest the possibility that the 
bacteria are downregulating these apoptotic pathways, yet the specifics of caspase-3 and 
apoptosis signaling pathways during F. tularensis infections are not completely clear. 
 
HOST IMMUNE RESPONSE TO FRANCISELLA INFECTION 
Innate immune response 
 Another pathogenic strategy of F. tularensis is to suppress the host pro-inflammatory 
immune response. This is one important difference between novicida and the more virulent 
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holarctica and tularensis subspecies. Whereas F. novicida stimulates the innate immune 
system, F. tularensis subspecies holarctica and tularensis does so to a much lesser extent and 
in a delayed manner due to active suppression on the part of these organisms (9, 35, 36, 46, 
53, 176, 270, 271). In fact, it has also been reported that both LVS and Schu S4 upregulate 
expression of the immunosuppressive cytokine TGF-β (35, 36). The pathways involved in 
response to F. tularensis, and which F. tularensis is suppresses, have only been partially 
elucidated. In terms of extracellular recognition, unlike many other Gram-negative bacteria, 
F. tularensis lipopolysaccharide (LPS) does not stimulate the host cell sensor protein toll-like 
receptor (TLR) 4 (2, 62, 128, 270). This low stimulatory effect is likely due in part to 
changes in lipid A, specifically the lack of a 4’-phosphate, which is removed by LpxF, and 
hypoacylation of the fatty acid chains (222, 278, 281, 282). There has been a fair bit of 
controversy on the exact structure of lipid A between the strains of Francisella (25, 222, 261, 
278, 282). Despite the inability of F. tularensis LPS to activate the host response, F. 
tularensis does stimulate TLR2, which recognizes lipoproteins, and whether this recognition 
is specific to TLR1/TLR2 or TLR6/TLR2 heterodimers is not clear, but F. tularensis may 
possibly stimulate both heterodimers with different ligands (2, 150, 168, 187, 274). 
Following stimulation of TLR2, several downstream pathways are required for immune 
activation. Overall, signaling occurs through MyD88 with a partial contribution of the 
MyD88 adaptor molecule TIRAP (2, 63, 65, 66, 199). This leads to downstream activation at 
least p38 and ERK1/2 MAPK, which presumably leads to activation of NF-κB and AP-1 
transcription factors for several pro-inflammatory cytokines, most notably pro-IL-1β (142, 
199, 270). LVS-infected cells display a TLR2- and MyD88-independent activation of PI3K 
that corresponded to a downregulation of p38 and ERK1/2, suggesting that PI3K and MAPK 
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signaling pathways may be involved in the suppression of the immune response observed for 
F. tularensis (199) . The specific downstream signaling pathways involved in suppression of 
pro-IL-1β transcription need further elucidation. 
 Processing of pro-IL-1β to mature IL-1β for secretion requires a two-step process. 
First, there must be transcription and synthesis of pro-IL-1β as described above. A second 
signal is required for processing into mature IL-1β in which a cytoplasmic sensor molecule 
recognizes a pathogen and then recruits additional protein components to form a complex 
called the inflammasome. The most well-characterized families of cytoplasmic sensors are 
the nucleotide binding domain leucine rich repeats containing proteins (NLRs) (145); 
however, there are reports of inflammasomes containing the cytoplasmic sensors absent in 
melanoma 2 (AIM2) or retinoic acid-inducible gene 2 (RIG-I) (44, 96, 97, 137, 225, 239). 
The respective sensor molecule will recruit procaspase-1, and then depending on the sensor 
molecule involved, also recruit the adaptor protein PYCARD/ASC (Pyrin-CARD/apoptotic 
speck-containing protein with a CARD) (71, 193). The formation of the complete 
inflammasome complex results in the auto-catalytic cleavage of pro-caspase-1 into caspase-
1, which can then process pro-IL-1β into mature IL-1β for secretion. 
 In terms of Francisella, ASC and caspase-1 are involved in detection of cytoplasmic 
Francisella bacteria (64, 113, 191). A recent study demonstrates that TLR2 and MyD88 are 
also required for inflammasome activation and assembly, but the mechanism is not clear 
(148). Once in the cytoplasm, F. tularensis stimulates the inflammasome via an unknown 
cytoplasmic receptor, although we know that F. tularensis does not stimulate the well-
characterized NLRP3 or NLRC4 (190, 191). There is some evidence that pyrin, a non-NLR 
cytoplasmic sensor, is required for inflammasome activation in response to F. novicida (114). 
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Several groups have published that a non-NLR sensor AIM2 recognizes F. tularensis DNA, 
which leads to inflammasome activation (97, 149, 232, 276); however, it is likely that this is 
not the only mechanism in play, and whether AIM2 is important for recognition by human 
cells is not clear. Type I interferon (IFN-α/β) is secreted in response to F. tularensis in a 
TLR-independent, interferon regulatory factor (IRF) 3-dependent manner and is necessary 
for caspase-1 processing, macrophage cell death, and IL-1β secretion (133). While Type I 
interferon secretion does not require the AIM2 inflammasome activation, Type I interferon 
and IRF-3 are required for activation of the AIM2 inflammasome in response to F. tularensis 
infection (97, 149). In contrast to these studies, another report argues that IFN-β is not 
required for inflammasome activation in DC’s or control of replication in this cell type but 
rather is important for the production of IL-12p40 (24). There is still a lot to learn about the 
inflammasome pathways activated in response to F. tularensis infection, and if and how F. 
tularensis is suppressing this arm of the pro-inflammatory pathway is not completely clear. 
 Many immunological studies with F. tularensis have been done in vivo or in 
macrophages, but several studies have addressed the specific roles of other cell types to the 
host innate immune response to F. tularensis infection. Interestingly, mast cells are recruited 
to the lymph nodes and lungs during pulmonary infection with F. tularensis LVS, and inhibit 
F. tularensis uptake and growth in macrophages as well as provide protection in a mouse 
model (153). The role of mast cells to control F. tularensis infection requires the cytokine IL-
4 and involves increased ATP production and phagosomal acidification of infected cells 
(153, 240). In endothelial cells, F. tularensis does not induce secretion of significant levels of 
pro-inflammatory chemokines and cytokines, specifically CCL2, MCP-1 and IL-8 by this 
cell type, and although neutrophil recruitment was involved, the neutrophils displayed 
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blunted responsiveness (98, 210).  The above data demonstrating downregulation of 
cytokines and chemokines makes sense in light of a study showing that both LVS and Schu 
S4 actively suppress the pro-inflammatory response of endothelial cells by acting through the 
anti-inflammatory endothelial protein C receptor (EPCR) (41). Type II epithelial cells 
exposed to F. tularensis secrete several cytokines and chemokines including IL-8, MCP-1, 
and GRO-α, and this secretion is NF-κB-dependent and promotes recruitment of neutrophils 
(116). Overall, these studies support the idea that F. tularensis also modulates the pro-
inflammatory response by altering chemokine release, leukocyte adhesion molecule 
expression, and subsequent recruitment of neutrophils, albeit less successfully. 
  
Adaptive immune response 
 The adaptive immune response to F. tularensis is largely a T-cell-mediated response 
and several T-cell populations are essential for resolution of infection (70, 72, 73, 89, 90, 
237). Interferon gamma (IFN-γ) was first shown to be required for an effective response to F. 
tularensis infection (103), with contribution of TNF-α that is thought to activate natural killer 
cells to secrete IFN-γ (166, 180). B-cells also play a minor role in protection against F. 
tularensis, and this B-cell response is independent of antibodies (77, 87). Not surprisingly, 
the immune response is dependent on the route of infection. Specifically, while IFN-γ is 
important in controlling infection following an intradermal inoculation, after intranasal 
inoculation during the subsequent infection in the lung, IFN-γ is not as important. Although 
T-cells are still involved, the composition and kinetics of the T-cell response in the lung is 
different than that of an intradermal infection (66, 67, 290). Instead, a role for Th17 cells has 
been shown following intranasal inoculation (290). Finally, there have been several F. 
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tularensis T-cell epitopes identified, with the most prominent epitope being a peptide from 
the outer membrane protein Tul4 (104, 120, 264, 265). 
 In addition to suppressing the innate immune response, Francisella also modulates 
the adaptive immune response to promote infection. As mentioned above, F. tularensis has 
been shown to suppress IFN-γ secretion (218). Another mechanism of suppression is through 
the induction of infected macrophages to secrete prostaglandin E2 (PGE2), which skews the 
T-cell response to an anti-inflammatory, Th2-like response by increasing IL-5 production 
(291). PGE2 has also been shown to be important in vivo following intranasal inoculation 
where it delays production of IFN-γ-positive T-cells and promotes IL-17 secretion and Th17 
cell production (74, 192, 290). Blocking IL-12 and producing IL-23, both of which result in 
an increase of Th17 cells, are also important in pulmonary infections of F. tularensis (47, 82, 
88). 
 
FRANCISELLA RESPONSE TO THE HOST 
 Despite the fact that F. tularensis is a successful pathogen, there is still a lot to learn 
about its virulence mechanisms, in part, because many of the classic virulence factors present 
in other bacterial pathogens have not been identified in F. tularensis (163). Furthermore, only 
recently have the genetic systems for large mutagenesis screens and generation of mutant 
libraries of F. tularensis been possible (23, 43, 112, 151, 168, 175, 184). In order to identify 
F. tularensis virulence factors, several genome-wide screens have been completed focusing 
either on intracellular replication, host cell cytotoxicity, phagosome biogenesis, or in vivo (3, 
4, 15, 156, 158, 183, 212, 228, 259, 267, 272, 284). From these screens, as well as in silico 
analyses, F. tularensis has been shown to have a capsule, Type IV pili, several proteases, iron 
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acquisition systems, and the Francisella Pathogenicity Island (FPI), all of which are 
discussed below. Other Francisella virulence factors include mviN (276), citrulline ureidase 
(182), a potassium uptake protein TrkH (7), minD (11), valAB (198), an alanine racemase 
(123), a purine biosynthetic enzyme with homology to glutamine 
phosphoribosylpyrophosphate amidotransferases (123), purMCD (220), purF (229), an AcrB 
RND efflux pump (31), OppB oligopeptide transporter (40), and FTL_0200 encoding a 
putative AAA+ ATPase of the MoxR subfamily (81). Finally, numerous hypothetical 
proteins were identified as virulence factors in the screens mentioned above and remain to be 
characterized. 
 
Francisella pathogenicity island 
 The FPI is an approximately 30 kb region consisting of 17 genes and located between 
inverted repeat sequences in the F. tularensis genome (213). Furthermore, the FPI is present 
in all F. novicida and F. tularensis strains, but while there is only one copy in F. novicida, 
the FPI is duplicated in F. tularensis (213). There are other differences in this region between 
strains. One major difference is found in the 3’ end of the FPI where holarctica strains are 
missing pdpD and anmK, and F. novicida encodes an additional 48 amino acids in PdpD 
(181, 213). The anmK gene has stop codon(s) inserted, differing on location and number 
between subspecies and clades, and the specific role for anmK in virulence is not clear (181). 
Before discovery of the FPI, one its component genes, iglC, was identified as encoding a 23 
kD protein that was upregulated during intracellular growth (121) and soon after, both iglC 
and iglABCD, one of the putative operons within the FPI, was shown to be required for 
intracellular growth (123, 157). Other individual genes within the FPI have been shown to be 
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required for virulence including pdpD (181, 213), pdpA (213, 256, 257), iglA and iglB (78), 
iglD (248),  pmcA/anmK (181), FTT_1347 (22), iglI (22, 38), and iglG (38). Interestingly, 
PdpE is not required for virulence (38). Of the FPI proteins, at least IglC (34, 170, 249), 
PdpA (256), IglD (34), IglG (38) and IglI (38), are important for phagosomal biogenesis 
and/or escape. Additionally, IglA and IglB have been shown to interact (78), but otherwise, 
the function of the FPI proteins are unknown.  
 There is some evidence that the FPI may encode a secretion system that is distantly 
related to the Type VI secretion system (T6SS) found in several other bacterial species (22, 
78). One study in F. novicida shows that the VgrG homolog (FTT_1347), is secreted into 
macrophages and in culture supernatants as observed for VgrG in other T6SS; however, 
unlike other T6SS, secretion of VgrG is independent of the known FPI T6SS homologs (22). 
Also unlike other characterized T6SS, the Hcp-homolog PdpE is not secreted in F. novicida 
(22). Curiously, using deletion mutants of either the FPI, vgrG, or the icmF homolog pdpB in 
F. novicida, it was shown that IglI is secreted and that this secretion is dependent on the FPI, 
VgrG, and PdpB (22). Overall, the studies on the FPI suggest that the proteins are part of a 
secretion system, potentially a novel secretion system similar but distinct from the T6SS. 
 
Regulation of virulence factors 
 Regulation of virulence factors in F. tularensis has been largely focused on the FPI 
genes. MglA is one of the key regulators of FPI gene transcription as well as at least 100 
other genes, including ones encoding secreted proteins PepO and BglX and genes involved in 
oxidative and general stress response (40, 124). MglA is also required for phagosomal 
escape, intracellular replication, and virulence in vivo (23, 34, 164, 249) and for replication in 
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mosquito and D. melanogaster cells (235, 246). In order to function as a transcriptional 
regulator, MglA binds to the RNA polymerase (RNAP) to direct transcription of the subset of 
genes mentioned above (52). This interaction with RNAP is dependent on MglA first binding 
to a protein called SspA and the MglA-SspA heterodimer then binding to RNAP; thus, the 
SspA regulon overlaps with that of MglA (52). Another regulator, MigR, regulates the FPI 
and other genes in the MglA/SspA regulon (39). FevR (also called PigR) has also been 
shown to regulate both FPI genes and other genes, and this regulation involves the small 
alarmone guanosine-tetraphosphate (ppGpp) which promotes the interaction between FevR 
and MglA to coordinate regulation of the same set of genes (42, 51).  
 Another distinctive aspect of F. tularensis is that the genome does not appear to 
encode any classic paired two-component regulatory systems, but does contain orphaned 
members (163). The orphan response regulator PmrA has been shown regulate the FPI as 
well as numerous other virulence genes and is required for both intracellular replication and 
in vivo pathogenesis (207, 244). More recently it was shown that PmrA is phosphorylated by 
a kinase KdpD and may interact with MglA and SspA (26). QseC is another orphan two-
component system member, which its partner, QseB, was only recently identified, and both 
genes were required for biofilm formation, typical of QseBC in other bacteria (84).  
 Another important F. tularensis regulator is Hfq, which traditionally acts as a post-
transcriptional regulator that facilitates the interaction between small non-coding RNAs in 
and RNA transcripts, which in turn decreases or enhances translation of the RNA transcripts. 
Hfq is not only valuable as a global regulator for stress tolerance, but also for its contribution 
to the regulation of virulence genes, including some genes found in the FPI (50, 200). 
Additionally, recent in silico and experimental analyses suggest that F. tularensis has several 
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non-coding small RNAs that are involved in gene regulation, although interactions with Hfq 
were not determined (226). In addition to virulence regulators, F. tularensis encodes the 
major sigma-70 factor (σ70), as well as a σ32 factor RpoH that regulates numerous genes 
required for heat-shock response (122).  
 Regulation of both gene and protein expression occurs in response to numerous 
environmental stimuli including inside the host macrophage (121, 283), different culture 
medias (43, 132, 293), heat shock (91, 122), osmotic and membrane stress (200), starvation 
and oxidative stress (91, 124, 167), mammalian body temperature (91, 138), iron limitation 
(79, 167), and glucose (138). A surprising result from a recent study demonstrated that F. 
tularensis alters gene expression in response to spermine and that this gene regulation is 
largely mediated through adjacent insertion sequence elements (48). 
 
Iron acquisition 
 As mentioned, F. tularensis gene expression changes in response to iron levels, which 
is not unexpected considering the iron is an essential metal that bacteria require for normal 
metabolism and is actively sequestered from pathogens by the host. The role of iron in F. 
tularensis infection was first observed in the context of iron acquisition upon phagosomal 
acidification in F. tularensis-infected cells (102). A common mechanism of iron uptake by 
bacteria is the use of siderophores, secreted iron-binding molecules. In F. tularensis, the 
fslABCDEF operon, is required for production of a siderophore similar to the 
polycarboxylate siderophore rhizoferrin and is required for iron acquisition and for growth in 
iron-limiting conditions (79, 154, 268). A highly conserved transcriptional regulator required 
during iron-limiting conditions is the ferric uptake regulator Fur, and F. tularensis encodes a 
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Fur protein that regulates genes involved in iron acquisition (79, 92, 93, 131). Later, fslE was 
also shown to be required for siderophore utilization, growth in iron-limiting conditions, and 
was under control of the Fur promoter as part of the fsl operon in Schu S4 (231). 
Interestingly, the F. tularensis genome does not appear to have tonB, exbB, or exbD, three 
genes encoding proteins that are typically required for siderophore uptake (163). Another 
protein recently described as being involved in both siderophore-dependent and -independent 
iron uptake by Schu S4 is FupA (FTT_0918) (171). In LVS, the FupA homolog (FTL_0439), 
which is a fusion protein of two adjacent genes in Schu S4, FupA/B, is required for 
siderophore-mediated iron uptake, and unlike Schu S4, FslE in LVS is considered a 
secondary player in siderophore-mediated iron uptake (260). FupA is required for virulence 
for both LVS and Schu S4 (171, 260, 275). These studies display some differences in iron 
uptake between Francisella strains, and both these differences as well as specific 
mechanisms of iron uptake need to be explained. 
  
Protection from oxidative stress  
 Oxidative stress can also induce the expression of iron uptake genes through 
activation of Fur as well as the regulator OxyR (294). In fact, F. tularensis subspecies 
tularensis displays decreased susceptibility to hydrogen peroxide killing that is associated 
with decreased intracellular iron content (172).  The role of reactive oxygen and nitrogen 
species in controlling intracellular bacterial infections in general is well understood. F. 
tularensis was first shown to be killed by nitric oxide in IFN-γ-activated macrophages and 
soon after,  host nitric oxide production was shown to be correlated with increased resistance 
to F. tularensis infection in vivo in a mouse model (103, 134). Using both peritoneal exudate 
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cells and mice deficient for production of reactive nitrogen and oxygen species, another 
group demonstrated more definitively that there are distinctive roles of reactive nitrogen and 
oxygen species to controlling both F. tularensis replication in host cells and an infection in 
vivo (170, 174)   Macrophages infected with F. tularensis have also been shown to 
upregulate proteins involved in the oxidative stress response of the macrophage (9, 283). 
Despite this host response, F. tularensis replicates within macrophages, as discussed above. 
In neutrophils, F. tularensis survives intracellularly, at least in part due to blocking the 
oxidative response through prevention of the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase formation and gp91/p22
phox
 or p47/p67
phox
 acquisition on the phagosome, 
and this blockage leads to a failure to control infection in vivo as well (83, 178, 179, 194, 
227).  
 F. tularensis encodes for several proteins involved in the response to oxidative stress 
common to other bacteria, though not many have been well-characterized. The superoxide 
dismutase SodB is required for virulence and for resistance to redox cycling agents paraquat 
and hydrogen peroxide (16). KatG, the catalase present in F. tularensis, is also required for 
resistance to the oxidative burst as well as for inhibition of pro-inflammatory signaling 
pathways, likely through PTEN, which is activated in oxidative conditions (173, 201). 
Finally, an attenuated strain of F. tularensis expressing a highly active form of AcpA was 
purified and shown to specifically inhibit the superoxide formation in neutrophils (236). 
AcpA in F. novicida was also shown to function as a phosphatase required for phagosomal 
escape (206). Later it was demonstrated that all four acid phosphatases, AcpABC and Hap, in 
F. novicida are required for the inactivation of the NADPH oxidase, resistance to phagocyte 
oxidative burst, and virulence in vivo (208, 209). Notably, in F. tularensis subspecies 
21 
 
tularensis and holarctica, AcpA is not required for inhibition of the oxidative burst, and 
AcpABC proteins are not required for Schu S4 virulence in vitro or in vivo (56, 195). 
Together these studies highlight a key difference between the human-virulent F. tularensis 
species and F. novicida.  
  
The capsule 
 A polysaccharide capsule is one common virulence factor found on many but not all 
pathogenic bacteria, likely including Francisella. The presence and type of capsule expressed 
by F. tularensis is a subject of debate. F. tularensis was originally shown to have a capsule-
like substance surrounding the bacterium over thirty years ago (55, 60, 136, 245). Mutants 
lacking this capsule structure demonstrate increased sensitivity to serum but reduced 
sensitivity to killing by neutrophils and are also avirulent in mouse models of tularemia (19, 
55, 245, 266). Furthermore, the composition and expression of the capsule can change 
depending on the growth conditions (55, 293). The F. tularensis capBCA locus has partial 
homology to the cap locus in B. anthracis that encodes for proteins needed to synthesize the 
poly-D-glutamic acid capsule (163, 185). Interestingly, while F. tularensis capBCA is 
required for intracellular growth and in mouse models of tularemia for both Schu S4 and 
LVS (69, 146, 202, 267), F. tularensis capsule has not been reported to consist of poly-D-
glutamic acid (202, 234). Early studies suggest that the capsule consists of carbohydrates, 
including mannose, rhamnose, and two other unidentified sugars, amino acids, and fatty acids 
(136). A more recent study found that the F. tularensis capsule is made up of O-antigen 
capsular polysaccharide and its production is dependent on the wbt O-antigen 
glycosyltransferases gene cluster (12). Three additional genes, FTT1236-1238 are also 
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required for O-antigen and/or O-antigen capsule formation (169). Besides the O-antigen 
capsular polysaccharide, higher molecular weight carbohydrate complex has also been 
identified in isolated capsule and consists of glucose, galactose, mannose, as well as 
Proteinase K-resistant protein, and this complex synthesis is dependent on the 
glycosyltransferase genes FTT_1422 and FTT_1423 (19). So although it is largely accepted 
that Francisella has a capsule, the composition, biosynthesis, and regulation of the capsule 
are not well defined. 
  
Type IV Pili 
 The use of type IV pili is a common way bacteria adhereto host cells and/or use for 
motility, yet the presence, composition, and function of type IV pili in Francisella are also 
subjects of debate. Type IV pili-like structures were first observed on LVS using microscopy 
(117) and later observed on F. novicida (117, 295) and Schu S4 (14). Pili formation in LVS 
and F. novicida is dependent on both the assembly ATPase PilB as well as the disassembly 
ATPase PilT (49, 295).  Surprisingly, in F. novicida pili formation is not dependent on PilC 
or PilQ, which are proteins typically required for pilus assembly in other bacteria, though it 
has yet to be determined whether this is the case for other Francisella strains (295).  
 In terms of pilus composition, PilA is typically the pilin subunit that makes up the 
pilus in Gram-negative bacteria; however, Francisella encodes six different pilin genes, 
pilA/pilE1, pilE/pilE2, pilV/pilE3, pilE4, pilE5, and pilE6. F. tularensis subspecies 
holarctica is the most divergent in the putative pilin genes. In several holarctica strains 
including LVS, pilA is absent from the genome, there are non-sense mutations in pilE/pilE2 
and pilV/pilE3, and the pilE4 sequence longer in length (163, 243). In F. tularensis 
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subspecies tularensis and holarctica and F. novicida strains that do encode for PilA, the only 
difference is found in the 3’ end of pilA in F. novicida (295). The role of these individual 
proteins in pilus composition has yet to be determined, and there are differences between 
subspecies. There is some evidence that the major pilin for F. novicida is PilE/PilE2 (295). 
Using heterologous expression of Schu S4 and F. novicida pilA in Neisseria gonnorhea, 
another group suggested that pilA is sufficient for pilus formation (242). Another recent study 
showed that in both LVS and Schu S4, pilE4 was required for pilus formation (14). 
Interestingly, pilE4 was not required for virulence; however, pilE5 and pilE6 were not 
required for pilus formation but were required for virulence in LVS only, again highlighting 
subspecies and species differences (14).   
 The role of the pil genes and pili formation to virulence is also different between 
strains. In terms of Schu S4, only recently was it demonstrated that pilA, pilE5, pilE6, 
pilC/pilG and pilQ are required for virulence in vivo, while pilT and pilE4 are not (14, 101). 
As explained above, of these, only pilE4 has been shown to be involved in formation of pili. 
For LVS, pilE5 and pilE6 were shown to be important for virulence in vivo, yet in two other 
holarctica strains, pilA was required for virulence in vivo (100). Finally, in F. novicida, the 
roles of pilA/pilE1 and pilE4 in virulence in vivo are variable between studies (127, 295).  
These discrepancies in a role for pili formation and the pil genes to virulence as well as 
among strains of Francisella only further complicate elucidation of the function of type IV 
pili. Some have ascribed virulence differences to a role for pili in Type II secretion, as 
discussed below. 
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Protein secretion 
 To date, all bacteria have (or are predicted to have/encode) mechanisms for secretion 
of effector molecules and proteins into the environment in order to support survival and 
replication, and Francisella is no exception. Although no toxins or other well-characterized 
secreted effectors have been identified in Francisella, several secreted proteases have been 
identified including ClpB heat shock protease (123), FTT1209c metallopeptidase family M13 
protein (40), PepO zinc protease (127), BglX beta-glucosidase (127), and hemolysins (160). 
Unlike many other pathogens, Francisella does not encode any classic Type III, Type IV, or 
Type V secretion system; however, there are Type I and Type II secretion systems as well as 
the cytoplasmic membrane Sec translocon (163, 189). For Type I secretion, TolC is the 
prototypical outer membrane efflux pump that interacts with inner membrane ATPases for 
secretion of toxic products. F. tularensis encodes a functional TolC protein involved with 
multidrug resistance and is required for intracellular replication and virulence in vivo (118, 
224). Francisella also encodes a putative secretion system in the FPI, as described above. 
 The Type II secretion system in Francisella is thought to be synonymous with Type 
IV pili encoded by the pil genes. The key difference is the use of GspC, GspL, and GspM as 
well as several periplasmic proteins in Type II secretion; however, Francisella does not 
encode GspC, GspL, and GspM, so it’s possible that the Type IV pili system is sufficient. 
Evidence of Type II secretion being functional in Francisella was determined by the 
observation that secretion of seven F. novicida proteins was dependent on pilA/pilE1, 
pilB/pilF, pilC/pilG, and pilQ, although these genes were not required for intracellular 
replication, they were important in vivo (127, 128, 295). Furthermore, pilE4, which is 
required for pilus formation in F. novicida, is not required for secretion (295). In LVS, pilE5 
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and pilE6 were not required for pilus formation but were required for virulence and the 
authors suggest a role for these proteins in secretion (14). Clearly, much remains to be 
elucidated in regards to mechanism and secreted effectors of Type II secretion as well as its 
relation to type IV pili and virulence. 
  
DISCOVERY AND INITIAL CHARACTERIZATION OF RIPA 
 Using a LVS transposon mutant library screen for intracellular replication in 
epithelial cells, our lab identified the locus FTL_1914. Deletion of this locus via allelic 
exchange resulted in an LVS mutant (LVS∆ripA) that is deficient for intracellular replication 
in both epithelial cells and macrophages and therefore was named ripA, required for 
intracellular proliferation, factor A (110).  Interestingly, LVS∆ripA escapes the phagosome 
and re-enters the autophagosome-like vacuoles with the same kinetics as wild-type (110). 
Both ripA gene expression and RipA protein expression are upregulated at higher pH 7.5 and 
ripA expression is also upregulated upon host cell infection, especially between 1-6 hours 
post invasion when bacteria have begun to enter the cytoplasm and replicate (111). 
Furthermore, deletion of the FPI transcriptional regulators mglA and sspA in LVS results in 
increased ripA expression, suggesting that these regulators inhibit ripA transcription. 
LVS∆ripA is also attenuated in a mouse model of pulmonary tularemia (110). A ∆ripA 
mutant in the highly virulent Schu S4 strain is also attenuated in a pulmonary mouse model 
and defective for intracellular replication (our unpublished results). Altogether these data 
suggest that ripA is required for virulence of F. tularensis. 
 RipA is a cytoplasmic membrane protein of 179 amino acids and approximately 17 
kD (110). While BLASTp analysis of the RipA protein sequence did not identify any 
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functional motifs or homologs with known functions, it revealed that there are RipA-like 
proteins found in select strains of a few randomly-distributed bacterial species (110). None of 
these RipA-like proteins have any known function. Interestingly, in a recent study RipA was 
identified as a glycosylated protein in a screen using lectin affinity chromatography (18). 
However, despite the importance of ripA to F. tularensis pathogenesis, the function of this 
protein is unknown. To address the question of RipA function, our lab began a search for 
RipA-interacting proteins. Since RipA was predicted to have two large cytoplasmic domains, 
we hypothesized that RipA likely interacts with cytoplasmic proteins. The search for RipA-
interacting proteins was initiated by means of immunoprecipitation using HA-tagged RipA 
and LVS lysates (109). These studies revealed a list of putative RipA-interacting proteins, 
one of which was confirmed using reciprocal pull-down experiments (109). This RipA-
interacting protein was named IclR due to its homology to the IclR family of transcriptional 
regulators (109). The F. novicida U112 IclR homolog had previously been described as being 
required for F. novicida virulence (284). Due to the role of IclR for the virulence of F. 
novicida and our results demonstrating an interaction with RipA, we considered that its role 
in virulence may be at least in part through its interactions with RipA.   
 Therefore, as described in chapter 2, we investigated the biological relevance of the 
IclR-RipA interactions through characterization of F. tularensis strains lacking iclR. In 
chapter 3, through the use of the ripA deletion mutant, we uncover a role for RipA in 
suppression of the immune response and elucidate pathways suppressed by wild-type F. 
tularensis. Finally, chapter 4 details work that characterizes RipA at the molecular and 
biochemical level in order to determine topology and to identify functional domains. 
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Together these studies help to elucidate RipA’s role in virulence and function, as well as 
reveal insights into the overall pathogenesis of F. tularensis. 
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Effects of the putative transcriptional regulator IclR on Francisella tularensis 
pathogenesis. 
 
 
 
 
Brittany L. Mortensen, James R. Fuller, Sharon Taft-Benz, Todd M. Kijek, Cheryl N. Miller, 
Max T.H. Huang, and Thomas H. Kawula 
 
 
 
 
Reprinted with permission from:  
Mortensen BL, Fuller JR, Taft-Benz S, Kijek TM, Miller CN, Huang MT, and Kawula TH. 
Effects of the putative transcriptional regulator IclR on Francisella tularensis pathogenesis. 
2010. Infection and Immunity. 78:5022-32. 
56 
 
ABSTRACT 
 Francisella tularensis is a highly virulent Gram-negative bacterium and is the 
etiological agent of the disease tularemia. IclR, a presumed transcriptional regulator, is 
required for full virulence of the animal pathogen, F. tularensis subspecies novicida U112 
(53). In this study, we investigated the contribution of IclR to the intracellular growth, 
virulence and gene regulation of human pathogenic F. tularensis subspecies. Deletion of iclR 
from the Live Vaccine and SchuS4 strains of F. tularensis subspecies holarctica and 
tularensis, respectively, did not affect their ability to replicate within macrophages or 
epithelial cells. In contrast to F. tularensis subspecies novicida iclR mutants, LVS and 
SchuS4 ∆iclR strains were equally virulent as their wild-type parental strains in intranasal 
inoculation mouse models of tularemia. Furthermore, wild-type LVS and LVS∆iclR were 
equally cytotoxic and induced equivalent levels of IL-1β expression by infected bone 
marrow-derived macrophages. Microarray analysis revealed that the relative expression of a 
limited number of genes differed significantly between LVS wild-type and iclR strains. 
Interestingly, many of the identified genes were disrupted in LVS and SchuS4 but not in their 
corresponding novicida U112 homologs. Thus, in spite of the impact of iclR deletion on gene 
expression, and in contrast to the effects of iclR deletion on F. tularensis subsp. novicida 
virulence, IclR does not contribute significantly to the virulence or pathogenesis of F. 
tularensis  
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INTRODUCTION 
 Francisella tularensis is a Gram-negative bacterium and the etiological agent of 
tularemia or “rabbit fever”. While zoonotic hosts include small mammals such as rabbits and 
voles, F. tularensis is also found in ticks, mosquitoes, and flies, and can replicate within 
amoebae as well (29). Human infection with F. tularensis can occur by several routes 
including bites by arthropod vectors (4, 5, 34), contact with contaminated tissues, ingestion 
of contaminated food or water (28, 43), or inhalation of aerosolized bacteria (18, 48). F. 
tularensis is considered a Select Agent by the Centers for Disease Control due to its low 
infectious dose (as few as 10 organisms) via the pulmonary route and its potential as a 
biological threat agent (15, 46). 
 There are two F. tularensis subspecies most commonly associated with disease in 
humans: F. tularensis subspecies tularensis (Type A) and F. tularensis subsp. holarctica 
(Type B). The Live Vaccine Strain (LVS) of subsp. holarctica is a useful model for studying 
the virulent F. tularensis subspecies, because it causes disease in mice, is attenuated in 
humans (19), and shares genomic and proteomic similarity with F. tularensis subsp. 
holarctica and tularensis (51). F. tularensis subsp. novicida, which does not cause disease in 
healthy humans, has significant similarity with subsp. holarctica and tularensis and is also 
used as model organism for studying F. tularensis pathogenesis. Although there are reports 
of subsp. novicida causing disease, these cases are commonly associated with 
immunocompromised individuals (2, 9, 24, 32). However, subsp. novicida does cause a 
severe disease in in vivo mouse models (40). 
 Francisella is known to predominately infect and replicate within macrophages but 
also infects and replicates within neutrophils (37), dendritic cells (3) and Type II alveolar 
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epithelial cells (23). After phagocytosis, F. tularensis escapes the phagosome and replicates 
within the cytoplasm of host cells (1, 10). Numerous in vitro and in vivo screens have 
identified virulence factors required for this intracellular life cycle (13, 14, 27, 30, 35, 41, 47, 
49, 53); however, many of the identified virulence factors have little or no similarity to 
known proteins of other bacteria and their functions remain, for the most part, unknown. 
 Weiss et al. recently identified a locus (FTN_0720) in F. tularensis subsp. novicida 
U112 that is important for virulence in mice as determined by an in vivo competition assay 
between a FTN_0720 deletion mutant and wild-type U112 (53). FTN_0720 encodes a protein 
with homology to the IclR family of transcriptional regulators. IclR family members activate 
and repress genes in a wide range of bacteria including genes involved in sporulation, 
metabolism, drug-efflux pumps and organic solvent tolerance, and phytopathogenicity (39). 
Given the close genetic relationship among the F. tularensis subspecies, the phenotype of the 
subsp. novicida iclR deletion strain suggests that IclR may be involved in the pathogenicity 
of the holarctica and tularensis subspecies. We investigated the contribution of IclR 
homologs in the pathogenicity of subsp. holarctica and tularensis by evaluating the role of 
IclR in gene expression, host cell interactions and virulence of F. tularensis subsp. holarctica 
LVS (FTL_1364) and subsp. tularensis SchuS4 (FTT_0748) strains. 
 
MATERIALS AND METHODS 
Bacterial strains.  
F. tularensis subsp. holarctica LVS was obtained from the CDC, Atlanta, GA. F. 
tularensis subsp. tularensis SchuS4 was obtained from BEI Resources. F. tularensis subsp. 
novicida U112 was obtained from the American Type Culture 88 Collection (ATCC). An 
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iclR transposon mutant was one of two mutants from the transposon mutant library (21) and 
was received as a gift from Colin Manoil. All strains were maintained on chocolate agar 
supplemented with 1% IsoVitaleX (Becton-Dickson), brain heart infusion (BHI) broth 
supplemented with 1% IsoVitaleX or Chamberlain’s defined medium (CDM) (6). 
Escherichia coli TOP10 (Invitrogen) were used for cloning purposes. E. coli was propagated 
in Luria broth supplemented with hygromycin at 200 μg/ml or kanamycin at 20 μg/ml as 
necessary for antibiotic selection. All cultures were grown at 37°C. 
 
Cell Culture.  
J774A.1 (ATCC TIB-67) cells are a macrophage-like cell line derived from mouse 
sarcoma reticulum cells and were cultured in Dulbecco’s minimal essential medium with 4.5 
g/L glucose, 10% fetal bovine serum, and 2 mM L-glutamine. TC-1 (ATCC CRL-2785) cells 
are a tumor cell line derived from mouse primary lung epithelial cells and were cultured in 
RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1.5 g/L sodium 
bicarbonate, 10 mM HEPES and 0.1 mM nonessential amino acids. Bone marrow-derived 
macrophages were generated by flushing bone marrow cells from C57BL/6 mouse femurs 
and recovered cells were incubated for 6 days on 15 cm
2
 non-tissue culture-treated dishes in 
L929 cell-conditioned DMEM. Nonadherent cells were removed by washing with phosphate-
buffered saline (PBS) and bone marrow-derived macrophages were recovered from the dish 
using 1 mM EDTA in PBS. 
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Molecular techniques and allelic exchange.  
For both LVS and SchuS4 the iclR deletion was generated by splice overlap extension 
(SOE) PCR using primers designed to amplify the 5’ and 3’ regions of the iclR locus, which 
were then annealed to their complementary, homologous genomic DNA tags (20, 25). The 
subsequent deletion left only the first six amino acids and the stop codon of iclR. Each 
construct was cloned into the pCR-Blunt II TOPO vector (Invitrogen), verified by DNA 
sequence analysis, and subsequently cloned into pMP590 (sacB Kan
r
) using BamHI and NotI 
restriction sites (20, 33). For allelic exchange, plasmids were electroporated into LVS or 
SchuS4 and integrants were selected on chocolate agar containing kanamycin (10 μg/ml). 
Kan
r
 strains were grown overnight and plated on 10% sucrose for counterselection (loss of 
plasmid) (20, 33). Both the LVS and SchuS4 iclR deletion strains were confirmed for loss of 
iclR by PCR. For complementation of the iclR deletion in LVS, iclR and its predicted 
promoter were PCR-amplified and subcloned into the pCR-Blunt II TOPO vector 
(Invitrogen). After a MluI/EcoRV restriction digest, the construct was ligated into the 
pMP633 low-copy Francisella shuttle vector (20) and electroporated into LVSΔiclR. 
Complementation was determined by detection of iclR in the complementation strain via 
PCR as well as demonstration of increased iclR transcript levels via microarray analysis (data 
not shown). 
 
Gentamicin protection assays.  
Gentamicin protection assays were performed as described (20, 23). Briefly, J774A.1 
murine macrophages, TC-1 murine lung epithelial cells, or bone marrow-derived 
macrophages were infected with LVS or SchuS4 at an MOI 100. Cells were incubated with 
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the bacterial inoculum for 2 hr (J774A.1 and bone marrow-derived macrophages) or 4 hr 
(TC-1) and then incubated with media containing 25 μg/ml gentamicin for an additional 2 hr 
to kill extracellular bacteria. At time points of 4 hr (or 6 hr for TC-1) and 24 hr, medium was 
removed, cells were washed with PBS and then scraped from the dish, and the bacteria 
serially diluted and plated to determine the number of viable bacteria. 
 
Mouse infections.  
6- to 8-week-old C57BL/6 mice were anesthetized intraperitoneally (i.p) with avertin 
and then inoculated intranasally (i.n.) with bacteria suspended in 50 μl PBS by application to 
the nares of each mouse or inoculated intradermally (i.d.) by injection into the tail using the 
same volume. Concentrations of LVS and U112 were determined by klett and concentrations 
of SchuS4 by spectrophotometer (OD600), and inocula were serially diluted and plated on 
chocolate agar to confirm the CFU administered. At the designated time points, mice were 
euthanized and the lungs, liver and spleen of each mouse were removed and homogenized. 
Serial dilutions of the homogenates were plated on chocolate agar to enumerate the bacterial 
organ burdens. Statistical significance between strains in each organ and at each time point 
was determined by the Mann-Whitney nonparametric test using GraphPad Prism v.5 
software. All animal experiments were performed according to the animal care and use 
guidelines as established by IACUC-approved protocols. 
 
IL-1β ELISAs and cytotoxicity assays.  
Bone marrow-derived macrophages were seeded in 12-well dishes at 1x10
6
 cells per 
well, and infected with bacteria at an MOI 500 in a final volume of 1 ml medium per well 
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and incubated at 37°C. After 24 hr, the supernatants from each well were collected, 
centrifuged to pellet cellular debris, and stored at -20°C. The IL-1β ELISA was performed 
using the BD OptEIA mouse IL-1β ELISA kit (BD Biosciences) according to the 
manufacturer’s protocol. The OD450 was read using a TECAN Infinite M200 and analyzed 
using Magellan v6 software. Cytotoxicity assays were performed using the ToxiLight® 
BioAssay kit (Lonza) following the manufacturer’s protocol for cytokine detection from 
supernatants, and the luminescence was read using a TECAN Infinite M200 and analyzed 
using Magellan v6 software. Statistical significance between each strain was determined by 
the student’s t-test using GraphPad Prism v.5 software. 
 
Microarrays.  
RNA was obtained using the RiboPure-Bacteria kit (Ambion) according to the 
manufacturer’s protocol. Briefly, bacteria were grown to early mid-log phase in CDM and 
pelleted. Cells were disrupted by suspension in Trizol and vortexing with 0.1 mm glass 
beads. Purified RNA was recovered by chloroform extraction followed by treatment with 
DNase I to remove DNA. Microarray analysis was performed following the guidelines 
provided by the Venter Institute for Genomic Research (SOP#M007, M008). Briefly, 
aminoallyl labeled cDNA was generated from 2 μg total RNA using SuperScript III reverse 
transcriptase (Invitrogen), random hexamers, and dNTPs containing aa-UTP. After removal 
of unincorporated aa-dUTP and free amines, labeled cDNA was coupled to Cy3 or Cy5 
mono-reactive dye (GE Healthcare). The Francisella microarray slides (Pathogen Functional 
Genomics Resource Center; PFGRC) contained 2331 70mer oligonucleotides in 
quadruplicates of the F. tularensis SchuS4 genome and several LVS genes as well as 
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quadruplicates of 70mer oligonucleotides for 500 Arabidopsis thaliana genes as controls. 
Slides were prehybridized in 5x SSC, 10% SDS and 1% BSA, washed and then hybridized 
with cDNA probes at 42°C. After post-hybridization washes, the slides were scanned using 
the GenePix 4000B scanner and GenePix Pro v6.0 software. The microarray data were 
normalized using the TIGR MIDAS v2.22 and analyzed using the TIGR Multiexperiment 
Viewer v 4.2.1 (MeV) as part of the TM4 Suite software (45). In MeV, pooled, normalized 
Cy5/Cy3 intensities from wild-type LVS control arrays were compared to pooled, normalized 
Cy5/Cy3 intensities from LVS∆iclR arrays. This list was filtered by statistical significance 
using Significance Analysis for Microarrays (SAM) provided on MeV after 179 an 80% cut-
off filter and using a false discovery rate of 5%. 
 
Quantitative RT-PCR.  
Quantitative RT-PCR was performed in a 96-well format using the SensiMix™ 
SYBR & Fluorescein One-Step kit (Bioline) following the manufacturer’s protocol. Briefly, 
50 ng of RNA isolated from wild-type or iclR mutant strains was mixed with SensiMix™ 
SYBR & Fluorescein, RNase inhibitors, and designated primers in a 20 μl volume. A 
genomic DNA ladder and a no reverse transcriptase control were analyzed using the 
SensiMix™ SYBR & Fluorescein kit following the manufacturer’s protocol with primers to 
gyrA. Thermocycling and detection was performed using the iCycler Thermal Cycler (Bio-
Rad). All starting quantity (SQ) values were normalized to the mean SQ value for gyrA. 
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Antibiotic sensitivity assays.  
F. tularensis LVS was grown to mid-log phase in BHI broth supplemented with 1% 
IsoVitaleX, the bacterial suspension was spread onto chocolate agar plates, and antibiotic-
containing filter paper discs were placed in the center of each plate. The rafampin (5μg), 
tetracycline (30μg), and colistin (10μg) were purchased pre-loaded from Becton Dickinson. 
The ampicillin and polymixin B discs were self-prepared by adding a 10 μl or 20 μl volume 
of antibiotic per disc at 10 μg ampicillin or 20 μg polymixin B. Bacteria were grown for 36 
hr and the diameter of the zone of inhibition was measured. 
 
Microarray data accession numbers.  
The raw and normalized microarray 199 data is available on the GEO database under 
the following accession numbers: GSM574374, GSM574375, GSM574376, GSM574377, 
GSM574379, GSM574380, and GSE23454. 
 
RESULTS 
Comparison of iclR alleles among F. tularensis subspecies and construction of iclR 
deletion mutants. 
The locus FTL_1364 is annotated as a hypothetical protein in NCBI; however, some 
of its homologs in other Francisella species are annotated as proteins belonging to the IclR 
family of transcriptional regulators. A search for conserved domains found within FTL_1364 
resulted in several related hits including a helix-turn-helix (HTH) domain conserved among 
IclR family members. Additionally, Francisella IclR has a C-terminal domain with high 
similarity to the IclR family profile Pfam01614. A recent publication describes a highly 
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specific IclR family member profile that lies outside the HTH domain and covers less than 
100 amino acids in the central region towards the C-terminal end (31). These authors classify 
current Pfam01614 members as belonging to the IclR family based on the new profile. 
Furthermore, BLASTp analysis of F. tularensis LVS or SchuS4 IclR reveals high similarity 
to IclR family proteins found across many bacterial species. F. tularensis IclR proteins share 
considerable amino acid identity (30-40%) and amino acid similarity (60%) with non-
Francisella IclR family proteins. Overall, the bioinformatic analysis strongly suggests that 
Francisella FTL_1364 and its homologous loci in other Francisella species encode a protein 
belonging to the IclR family of transcriptional regulators. 
 Using NCBI and the Francisella genome browser (www.francisella.org) for 
annotations and synteny analysis, we found that the iclR locus has shared characteristics 
among F. tularensis subsp. novicida U112, F. tularensis subsp. holarctica LVS, and F. 
tularensis subsp. tularensis SchuS4 strains (FTN_0720, FTL_1364 and FTT_0748, 
respectively), (Figure 1A). On one side of iclR in each strain is a gene encoding a predicted 
protein with similarity to an esterase lipase (FTL_1363, FTN_0721, and FTT_0749). On the 
other side of iclR is a gene encoding a predicted protein with similarity to the multidrug 
efflux protein EmrA (FTL_1365-66, FTN_0718, and FTT_0747). One difference is that 
EmrA is divided into two ORFs in LVS. There are other differences in the length and coding 
sequences of this genetic region, including an additional open reading frame in U112 that 
encodes a predicted protein of unknown function FTN_0719. Nevertheless, in each strain, 
iclR is located in a similar region of the genome. 
 Additionally, iclR itself is highly conserved among the three F. tularensis strains 
U112, LVS and SchuS4. SchuS4 iclR has three nucleotide differences compared to iclR from 
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LVS that translate into two amino acid differences, S22G and H78Y, between LVS and 
SchuS4 IclR. U112 iclR has 95 nucleotide differences compared to LVS iclR and 94 
nucleotide changes compared to SchuS4 iclR. Although this results in a three nucleotide 
truncation of U112 iclR, there is 80% amino acid identity between U112 IclR and SchuS4 
and LVS IclR proteins (Figure 1B). While these similarities suggest that IclR is conserved 
among the U112, LVS, and SchuS4, there are a sufficient number of differences to account 
for possible functional deviations between these strains as well. Due to genetic similarity and 
the contribution of IclR to the virulence for F. tularensis subsp. novicida, we investigated the 
potential contribution of IclR to the virulence of F. tularensis subspecies holarctica and 
tularensis. To do this, we made a clean deletion of the iclR gene in the F. tularensis 
subspecies holarctica LVS (LVSΔiclR) and tularensis SchuS4 (SchuS4ΔiclR) using SOE 
PCR and allelic exchange in LVS (FTL_1364). We also generated an iclR complementation 
strain by expression of iclR on a low-copy shuttle vector. 
 
LVS and SchuS4 iclR deletion mutants are competent for intracellular replication. 
 One method to assess the contribution of IclR to F. tularensis virulence is to 
determine what role IclR plays in intracellular replication. We used gentamicin protection 
assays in the J774A.1 murine macrophage-like cell line and the TC-1 murine lung epithelial 
cell-like cell line to assess intracellular replication by iclR deletion mutant strains. Both 
LVSΔiclR and wild-type LVS replicated approximately two logs by 24 hr in both J774A.1 
and TC-1 cells (Figure 2A-B). We also performed these assays in bone marrow-derived 
macrophages, and both wild-type LVS and LVSΔiclR replicated intracellularly in these cells 
(Figure 2C). Similarly, the intracellular replication of SchuS4ΔiclR was similar to wild-type 
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SchuS4 in J774A.1 cells (Figure 2D). These results demonstrate that IclR is not required for 
intracellular replication of LVS or SchuS4 in these cell types. 
 
LVSΔiclR is not attenuated following intranasal or intradermal inoculation of mice. 
 Properties other than intracellular replication contribute to F. tularensis pathogenesis. 
We therefore determined whether IclR was required for LVS virulence in vivo. To test this, 
we used a mouse model of pulmonary tularemia in which we inoculated C57BL/6 mice i.n. 
with a lethal dose (1x10
5
 CFU) of LVS or LVSΔiclR. At 1, 3, 7 and 8 days post inoculation 
the lungs, liver and spleen were harvested to enumerate the bacterial organ burdens (Figure 
3A). These initial experiments revealed that there were no differences in the organ burdens at 
1 or 3 days post inoculation. At day 7, there appeared to be slight differences in the organ 
burdens in the liver and spleen, and by day 8 the organ burdens in the liver and spleen had 
not increased. These initial experiments suggested that LVSΔiclR may demonstrate enhanced 
clearance in the mouse. This would correlate with previously published data demonstrating a 
decrease in competitive index in the spleen at 48 hr for the subsp. novicida U112 iclR 
deletion mutant compared to wild-type novicida U112 (53). 
 To further investigate the possibility of a more subtle phenotype of enhanced 
clearance, we used a low dose (1x10
3
 CFU) i.n. inoculation of groups of six wild-type 
C57BL/6 mice with LVS or LVSΔiclR. At days 1, 3, 7 and 10 post inoculation, we again 
harvested the lungs, liver and spleen to calculate the bacterial organ burdens. There were no 
significant differences between the bacterial organ burdens of LVSΔiclR or wild-type LVS at 
any time point (Figure 3B). This suggests that LVSΔiclR is not attenuated in a mouse model 
of pulmonary tularemia. 
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 Since the experiments with subsp. novicida U112 iclR deletion mutant were 
performed using subcutaneous (s.c.) and i.p. inoculation, we investigated whether a role for 
iclR in pathogenesis may be route-specific. Groups of 6 to 7 wild-type C57BL/6 mice were 
infected i.d. with 3x10
5
 CFU of LVS or LVSΔiclR. The i.d. route has a comparable LD50 
dose and is similar in nature to the s.c. route (17). At 1, 3, and 7 days post inoculation, we 
again harvested the lungs, liver and spleen and determined bacterial organ burdens. At each 
time point and in each organ, there was no significant difference in the bacterial burdens 
comparing LVS and LVSΔiclR (Figure 3C). These data indicate that in LVS, iclR is not 
required for pathogenesis in the mouse via the i.n. or i.d. route. 
 
SchuS4ΔiclR is not attenuated following intranasal inoculation of mice. 
 Although iclR does not appear to be required for LVS pathogenesis, it is possible that 
iclR plays a role in SchuS4 pathogenesis. We inoculated groups of four wild-type C57BL/6 
mice i.n. with a lethal dose (100 CFU) of wild-type SchuS4 or SchuS4ΔiclR. At 1 and 3 days 
post inoculation, the lungs, liver and spleen were harvested to enumerate the bacterial organ 
burdens of infected mice (Figure 4). At both time points and in each organ, there were no 
differences in bacterial burden between wild-type SchuS4 and SchuS4ΔiclR. These data 
suggest that IclR does not play a role in the in vivo virulence of SchuS4 when assessed by the 
mouse model of pulmonary tularemia. 
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A subsp. novicida U112 iclR transposon mutant is attenuated following intranasal 
inoculation of mice. 
 As noted above, an iclR deletion mutant in subsp. novicida U112 displays decreased 
competitive index in the spleen following s.c. and i.p inoculation of mice (53). Therefore, we 
wanted to determine whether iclR is required for subsp. novicida U112 pathogenesis in a 
pulmonary mouse model. We inoculated groups of six wild-type C57BL/6 mice i.n. with a 
dose of approximately 10 CFU of wild-type U112 or a U112 iclR transposon mutant. At 1 
and 5 days post inoculation, the lungs, liver and spleen were harvested and the bacterial 
organ burdens were enumerated. Each organ had reduced burdens of the iclR transposon 
mutant compared to wild-type U112, and at day 5 these differences were statistically 
significant in the liver and spleen (Figure 5). These data suggest that iclR is required for 
U112 pathogenesis via the i.n. route and correlates with the previously published data using 
the s.c. and i.p. routes. 
 
Deletion of iclR does not affect IL-1β expression or cytotoxicity of infected cells. 
 To determine if there is an altered cellular response to LVSΔiclR compared to wild-
type LVS, we measured the production of pro-inflammatory cytokines by infected cells. 
Bone marrow-derived macrophages were infected at an MOI 500 with LVS or LVSΔiclR and 
the supernatants were analyzed for IL-1β at 24 hr post infection (Figure 6A). The levels IL-
1β measured in the supernatants of LVSΔiclR-infected cells was similar to that of cells 
infected with wild-type LVS, and no differences between strains were statistically 
significant. 
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 F. tularensis is also reported to induce cytotoxicity of infected macrophages. To 
determine whether there was a change in cytotoxicity induced by LVSΔiclR, we infected 
murine bone marrow-derived macrophages with LVS or LVSΔiclR at an MOI 500 and 
performed cytotoxicity assays on supernatants collected at 24 hr post infection. As shown in 
Figure 6B, LVSΔiclR induces cytotoxicity in infected cells to a level similar to that of wild-
type LVS, and no differences between strains were statistically significant. 
 
The effects of IclR on gene expression. 
 Due to its homology to transcriptional regulators, we used microarray analysis to 
determine what genes in LVS were affected by IclR by comparing gene expression between 
the LVSΔiclR mutant and wild-type LVS. We grew LVS and LVSΔiclR to mid-log phase to 
harvest RNA for reverse transcription and amino-allyl labeling of cDNA, and the labeled 
cDNA was hybridized to microarray slides. The slides are printed for every annotated ORF 
for SchuS4, plus LVS alleles that are either not present or are variant in SchuS4, but they are 
not tailored to F. tularensis subsp. novicida. Three separate microarrays from independent 
RNA samples were pooled and statistically significant gene expression differences between 
LVSΔiclR and wild-type LVS were determined by SAM (Table 1). Genes exhibiting 
significant changes in expression are listed by the provided locus annotations, LVS or 
SchuS4, as printed on the slides. 
 Using the above criteria, we identified 13 downregulated and 4 upregulated genes in 
LVSΔiclR. The list of genes identified comprises diverse functional groups suggesting that 
IclR does not impact expression of one specific functional group of proteins. There were 
several IclR-affected genes annotated as encoding hypothetical proteins. To get a better idea 
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of what types of proteins these genes may be encoding and possibly obtain insight on IclR 
function, we performed BLASTp analyses. Many of the proteins were only conserved in 
Francisella with no similarity to proteins or conserved domains in other bacteria. However, 
there were several with similarity to known proteins in other bacteria and these are described 
in Table 1. Although most of the genes were represented exclusively by the SchuS4 allele, 
there were two cases where the SchuS4 and LVS homologs were both printed on the 
microarray slide and also appeared on the gene list as having significant expression changes 
in the absence of IclR. FTT_0741c and its FTL_1373 homolog were both upregulated in 
LVSΔiclR, and both FTL_0388 and its homolog FTT_0885 were downregulated in 
LVSΔiclR. Overall, although further studies need to be performed to demonstrate a function 
of IclR, both bioinformatic and microarray data suggest that Francisella IclR could function 
as a transcriptional regulator. 
 
Comparison of IclR-regulated genes between LVS, SchuS4 and U112. 
 One explanation for the phenotypic differences observed for iclR mutants among the 
F. tularensis U112, LVS and SchuS4 strains could be due to differences in the genes affected 
by IclR among the strains. To address this we performed a more detailed examination of the 
genes on our microarray list. First, we performed synteny analysis using the genome synteny 
tool at www.francisella.org to determine whether each gene was annotated in SchuS4, LVS 
and U112. We observed that there were a few genes that were not annotated or not present in 
all three strains, as shown in Table 1. Secondly, we generated alignments and protein 
translations of the genes using Vector NTI software based on the NCBI annotation or the 
putative loci of non-annotated genes from the synteny analysis, if they were found. For 
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example, sequence alignments revealed that in LVS there is an unannotated ORF between 
FTL_1120 and FTL_1121 bearing homology to FTT_1082. Nearly half of the genes were 
similarly annotated and encoded one intact open reading frame (ORF) in SchuS4, LVS and 
U112. However, a significant percentage of genes displayed considerable sequence 
differences between strains as described in Table 1. 
 Of these genes, many were not intact in the virulent strains LVS and/or SchuS4, 
whereas the homologous genes in U112 were intact. For example, FTL_1506 and FTL_1507 
are pseudogenes because they encode two ORFs while their SchuS4 (FTT_0723c) and U112 
(FTN_0634) encode only one ORF. One special case is FTT0715, which along with its LVS 
homolog FTL_1521, has two large deletions, 131bp (119bp in LVS) and 197bp, when 
compared to the U112 homolog FTN_0627. The significance of these deletions cannot be 
inferred, and though these genes are not pseudogenes, the fact that these large deletions are 
present only in SchuS4 and LVS is noteworthy. This also highlights the fact that many of the 
intact genes on the microarray list have greater overall sequence differences between U112 
and LVS or SchuS4 when compared to that of the differences between LVS and SchuS4. 
  We next wanted to determine whether the set of genes that were changed in 
expression in LVSΔiclR were also changed in the absence of IclR in U112. First, we 
performed quantitative RT-PCR on six genes that were differentially-regulated in the 
microarray for LVS versus LVSΔiclR (Figure 7A) and normalized to the housekeeping gene 
gyrA. We also included iclR. As expected, we detected a dramatic decrease in iclR transcript 
in LVSΔiclR and negligible change in gyrA. Of the six genes analyzed, four repeated the 
trend seen in the microarray analysis. For the two genes that did not, the primers appeared to 
amplify with similar efficiencies to other primers (data not shown). Overall, the qRT-PCR 
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data supports the fact that the genes identified in our microarray are changed in expression in 
the absence of IclR using a different method. We then tested the same set of gene homologs 
on RNA isolated from wild-type U112 and the U112 iclR transposon mutant (Figure 7B). 
Quantitative RT-PCR first verified that iclR transcripts were substantially lower in the 
transposon mutant. Overall, the six selected genes appear to be changed similarly to their 
LVS homologs, suggesting a similar set of genes affected by IclR in U112. These analyses 
do not account for any additional genes affected by U112 IclR that were not affected by LVS 
IclR as detected by microarray. Furthermore, these analyses alone are not sufficient to 
extrapolate any correlations in terms of IclR function or which of the IclR-affected genes are 
likewise impacted at the protein level or functional. 
 
The effects of IclR on antibiotic resistance. 
  Other IclR family proteins are known to be involved in the regulation of multi-drug 
efflux pumps (39). In all three F. tularensis subspecies, iclR is located near ORFs encoding 
hypothetical proteins that have homology to the EmrA multidrug efflux pump. In LVS, the 
two ORFs encoding proteins with EmrA homology that are found upstream of iclR were not 
changed in expression as determined by our microarray analysis. Nevertheless, the 
microarray data for LVSΔiclR showed increased expression of a gene encoding a protein 
with homology to organic solvent tolerance proteins, suggesting that IclR may be involved in 
repression of some genes involved in drug efflux. Organic solvent tolerance is often 
associated with multi-drug efflux pumps, most notably in Escherichia coli and Pseudomonas 
putida (42). Furthermore, our BLASTp analyses of hypothetical genes that appear in the 
LVSΔiclR microarray gene list also reveal proteins with homology to other transporter 
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proteins. To determine whether iclR is involved with drug efflux, we performed disc 
diffusion assays using a panel of antibiotics. Antibiotics selected for analysis were chosen as 
representatives from several classes of antibiotics targeting cell wall synthesis, protein 
synthesis, nucleic acid synthesis, and cell membrane integrity. There was no difference in 
antibiotic sensitivity between wild-type LVS and LVSΔiclR using this method (Figure 8). 
 
DISCUSSION 
 Herein we investigated the contribution of the putative transcriptional regulator IclR 
to F. tularensis pathogenicity. In this study, we found that the LVSΔiclR was not attenuated 
for intracellular replication in J774A.1 macrophage-like cells, TC-1 epithelial cells, or bone 
marrow-derived macrophages. Similarly, SchuS4ΔiclR was not attenuated for replication in 
J774A.1 cells. These data are consistent with published data by Weiss et al. for the novicida 
U112 iclR deletion mutant strain in bone-marrow derived macrophages (53). 
  When compared to wild-type LVS, LVSΔiclR did not impact IL-1β induction or 
cytotoxicity of infected cells, which is different from that of the published novicida studies 
(53). It is important to note that the methods used for these analyses were different between 
the two studies. The levels of IL-1β that we reported in this study are near but not below the 
limit of detection for the ELISA. The fact that the levels of IL-1β induced are low is 
consistent with other studies evidencing that LVS suppresses the inflammatory response (26, 
50). Furthermore, Weiss et al. used pre-stimulated bone marrow-derived macrophages, 
whereas we used naïve bone marrow-derived macrophages. Macrophages pre-treated with 
LPS or heat-killed F. tularensis subp. novicida as well as thioglycolate-elicited macrophages 
produce higher levels of IL-1β in response to infection (11, 12, 36, 52). Another possibility is 
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that there are strain-specific differences in the role of IclR, as evidenced by the results of the 
in vivo studies discussed below. 
  Unlike the novicida iclR deletion mutant, neither LVSΔiclR nor SchuS4ΔiclR were 
attenuated in mice following i.n. inoculation. There were differences in the experimental 
design between our studies and the novicida study. We initially inoculated mice i.n. and 
monitored lung, liver, and spleen over several days post infection. Weiss et al. used s.c. and 
i.p. inoculations in competition assays examining the spleen at 2 days post infection. It is 
possible that inoculation route may have an impact on the importance of IclR on establishing 
infection. To address the possibility that the phenotype is route-specific, we performed a 
reciprocal analysis by evaluating the virulence of LVS and U112 iclR mutants in i.d. and i.n. 
infection models, respectively. The results confirmed that the Francisella virulence-specific 
properties of IclR are restricted to subspecies novicida. 
  It is not clear why IclR is required for virulence in U112 but not LVS and SchuS4. 
Based on our microarray analysis, the subspecies-specific sequence differences among IclR-
affected genes could contribute to the functional differences we observe for IclR between 
subspecies. Many of the genes are intact in U112, but in LVS and/or SchuS4, the 
homologous genes are pseudogenes or displayed significant sequence variation (e.g. two 
large deletions in FTT0715/FTL_1521). The virulent subspecies of F. tularensis are noted for 
their genome decay as characterized by smaller genomes as well as increased numbers of 
pseudogenes, transposases and gene rearrangements (51). Genome-wide analyses of 
Francisella strains support this idea and many of the genes changed in LVSΔiclR that we 
identified to be pseudogenes correlate with those found in other studies (7, 44). It is possible 
that IclR in subspecies novicida exerts its effects on genes that are intact whereas in LVS and 
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SchuS4, IclR affects genes that are similar those in novicida but because of disruptions or 
changes to the ORFs, many of these genes are transcribed but do not encode functional 
proteins. We must also consider that there are two genes in the list that are absent in U112 
that are present in LVS and SchuS4, and the absence of a gene affected by IclR in novicida 
could also contribute to the different phenotypes. Overall, analysis of the genes identified in 
our microarray suggest that the majority of genes affected by IclR have differences in 
sequence between the three subspecies and that this variation could contribute to the 
phenotypic disparities observed. 
  Taken together, our data suggest that IclR contributes to the virulence of U112 but 
not to that of LVS or SchuS4, highlighting the fact that there are significant differences 
among these strains. Another example of differences among strains is seen in the conserved 
acid phosphatases AcpA, AcpB, and AcpC. These proteins were shown to be required for the 
virulence of subsp. novicida, but not for the virulence of SchuS4 (8, 38). Even though IclR 
may not play a major role in SchuS4 or LVS virulence, there are other potential roles that 
IclR could be have as a functional transcriptional regulator. Quite a few of the microarray-
identified genes encode hypothetical proteins, but there are others that encode proteins with 
known functions or are homologous to proteins with known functions. Investigation into 
these proteins may provide an additional understanding of the function of IclR in F. 
tularensis. For example, in Pseudomonas putida, the IclR family proteins TtgT and TtgV 
regulate operons encoding genes that form efflux pumps for organic solvent extrusion (16, 
22). Although our antibiotic sensitivity assays showed no role for IclR in drug efflux by 
LVS, we cannot rule out the involvement of IclR in the regulation of a system specific for 
organic solvent efflux or the role of IclR in drug efflux in other F. tularensis subspecies. 
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Finally, direct comparison of the complete transcriptional profiles of subspecies novicida, 
tularensis and holarctica iclR deletion strains might reveal some clues to the properties that 
are responsible for the phenotypic differences. Unfortunately, the currently available 
microarrays do not contain targets for genes found exclusively in subspecies novicida. 
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FIGURES 
 
 
 
 
 
 
 
Figure 1. Comparison of iclR in three Francisella strains. (A) Synteny diagram of the 
genomic organization of the iclR locus in F. tularensis subspecies novicida U112 
(FTN_0720), F. tularensis subspecies holarctica LVS (FTL_1364), and F. tularensis 
subspecies tularensis SchuS4 (FTT_0748). (B) Amino acid sequence alignment of F. 
tularensis subspecies novicida U112, F. tularensis subspecies holarctica LVS, and F. 
tularensis subspecies tularensis SchuS4 IclR. Alignment was created using VectorNTI 
software and iclR sequences uploaded from NCBI annotated genomes of each strain and 
translated using VectorNTI. Red letters highlight residues conserved between all three 
strains. Blue letters highlight the residues conserved between two strains. 
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Figure 2. Intracellular replication of LVS∆iclR and SchuS4∆iclR in murine 
macrophages or lung epithelial cells. Gentamicin protection assays were performed by 
infecting (A) J774A.1 murine macrophages, (B) TC-1 murine lung epithelial cells, and (C) 
bone marrow-derived macrophages with wild-type LVS or LVS∆iclR at an MOI 100. (D) 
Gentamicin protection assay was performed using J774A.1 cells infected with wild-type 
SchuS4 or SchuS4∆iclR. Bars represent the standard deviation of three replicate wells and 
each graph is representative of two separate experiments. 
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Figure 3. Recovery of LVS∆iclR mutant in mice following i.n. or i.d. inoculation. 
C57BL/6 mice were inoculated with either wild-type LVS (circles) or LVS∆iclR (triangles) 
i.n. at (A) a lethal dose of ~1x10
5 
CFU or (B) a low dose of ~1x10
3
 CFU. (C) C57BL/6 mice 
were inoculated with either wild-type LVS (circles) or LVS∆iclR (triangles) i.d. at a dose of 
~3x10
5
 CFU. Each symbol represents data from a single mouse. There were no significant 
differences in recovery of mutant versus wild-type organisms from any organ at any time 
point as determined by the Mann-Whitney nonparametric test in the low dose (B) and i.d. (C) 
experiments. 
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Figure 4. Recovery of SchuS4∆iclR mutant in mice following i.n. inoculation. C57BL/6 
mice were inoculated with either wild-type SchuS4 (circles) or SchuS4∆iclR (triangles) i.n. at 
a dose of ~100 CFU. No differences in recovery of mutant versus wild-type organisms from 
any organ at any time point were significant using the Mann-Whitney nonparametric test. 
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Figure 5. Recovery of U112 iclR transposon mutant in mice following i.n. inoculation. 
C57BL/6 mice were inoculated with either wild-type U112 (circles) or U112 iclR mutant 
(triangles) i.n. at a dose of ~10 CFU. Differences in recovery of mutant versus wild-type 
organisms at day 5 for the liver and spleen were significant using the Mann-Whitney 
nonparametric test. 
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Figure 6. IL-1β release and cytotoxicity in murine bone marrow-derived macrophages 
infection with LVS∆iclR. Infections were carried out at an MOI 500 for wild-type LVS, 
LVS∆iclR, and LVS∆iclR + IclR (complementation). (A) IL-1β was quantified via ELISA 
and (B) cytotoxicity was quantified via ToxiLight bioassay (Lonza), both at 24 hr post 
infection. Graphs are representative of at least three separate experiments, with duplicate or 
triplicate wells for each strain per experiment. No differences were significant by any strain 
comparison using the student’s t-test. 
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Figure 7. Transcript levels of genes found significantly changed in microarray analysis 
comparing LVS and LVSΔiclR. RNA was isolated from (A) wild-type F. tularensis subsp. 
holarctica LVS and LVSΔiclR or (B) wild-type F. tularensis subspecies novicida U112 and a 
U112 iclR transposon mutant and used in qRT-PCR analysis for several genes that were 
significantly changed in the microarray. Data is presented as relative expression of log 
change in wild-type over the respective iclR mutant after normalization to gyrA. Graph is 
representative of two or three experiments. 
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Figure 8. Antibiotic sensitivity of LVS∆iclR. Wild-type LVS and LVS∆iclR were grown to 
mid-log phase, bacteria spread on chocolate agar, and an antibiotic-containing paper disc was 
added to the center. Bacteria were grown for 36 hr and the diameter of the zone of inhibition 
was measured. Experiment was performed in triplicate and the averages and standard 
deviations were calculated. 
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CHAPTER 3 
 
Deletion of ripA alleviates suppression of the inflammasome and MAP kinase by 
Francisella tularensis 
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ABSTRACT 
Francisella tularensis is a facultative intracellular pathogen and potential biothreat 
agent. Evasion of the immune response contributes to the extraordinary virulence of this 
organism although the mechanism is unclear.  While wild type strains induced low levels of 
cytokines, an F. tularensis ripA deletion mutant (LVSΔripA) provoked significant release of 
IL-1β, IL-18 and TNF-α by resting macrophages. IL-1β and IL-18 secretion was dependent 
on inflammasome components PYCARD/ASC and Caspase-1, while the TLR/IL-1R 
signaling molecule, MyD88, was required for inflammatory cytokine synthesis. 
Complementation of LVSΔripA with a plasmid encoding ripA restored immune evasion. 
Similar findings were observed in a human monocytic line. The presence of ripA nearly 
eliminated activation of MAP kinases including ERK1/2, JNK and p38 while pharmacologic 
inhibitors of these three MAPKs reduced cytokine induction by LVSΔripA. Animals infected 
with LVSΔripA mounted a stronger IL-1β and TNF-α response than mice infected with wild 
type LVS. This analysis revealed novel immune evasive mechanisms of F. tularensis.     
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INTRODUCTION 
Francisella tularensis is a Gram-negative, facultative intracellular pathogen that is 
the causative agent of the zoonotic disease tularemia. The organism can be transmitted to a 
host through insect bites, handling of infected carcasses, and inhalation of aerosolized 
bacteria (1-3). F. tularensis is a potential agent of biological warfare classified as a Select 
Agent by the Center for Disease Control (CDC) due to its highly infectious nature; roughly 
50% mortality is caused by an infectious dose of as few as 10 bacteria via inhalation (4). 
During the Cold War, both the former Soviet Union and the United States of America 
weaponized and stockpiled F. tularensis in their biological weapons programs (5). The 
World Health Organization (WHO) has estimated that a 50 kilogram release of F. tularensis 
over a 5 million metropolis would cause 250,000 incapacitating casualties and 19,000 deaths 
(WHO 1970). The CDC also estimated that a F. tularensis attack would cost 5.4 billion to the 
society for every 100,000 infected individuals (6). Four subspecies of F. tularensis exist, 
including tularensis, holarctica, mediasiatica, and novicida (7). The most virulent subspecies 
for humans is the subsp. tularensis which is found primarily in North America. Subsp. 
holarctica is less virulent and was used to generate a live vaccine strain (LVS). LVS is 
attenuated in humans but remains highly virulent for mice making LVS a useful model to 
study F. tularensis pathogenesis.  
Since exposure to the respiratory tract results in the most aggressive form of 
tularemia, several laboratories have developed mouse models of pulmonary tularemia to 
study this mode of infection (8-10). Using an intranasal delivery model, the median lethal 
dose (LD50) of LVS is 10
3 
CFU (9). By comparison, the LD100 for the highly virulent F. 
tularensis subsp. tularensis strain SchuS4 is less than 20 CFU (11). Upon inhalation, the 
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bacteria are restricted to the lung for approximately 36 to 48 hours where the organism 
persists and multiplies (12). During this time, little host immune response occurs as 
evidenced by the lack of pro-inflammatory cytokines IL-1β, TNF-α, IL-6 and IFN-γ (13). 2-4 
days post infection, inflammatory cells infiltrate the lung and pro-inflammatory cytokines 
can be detected in vivo. By this time, bacteria have overwhelmed the lung and disseminated 
to other organs such as the spleen and liver. Mice eventually succumb to infection 5-7 days 
post inoculation. How F. tularensis circumvents the host immune response is not well 
understood. 
F. tularensis is found in vivo within alveolar macrophages, dendritic cells (DC) and 
lung epithelial cells (9). Following entry into host cells, F. tularensis escapes the phagosome 
and enters the cytosol where it replicates. This process is apparently unhindered by innate 
immune defenses that typically detect and facilitate a response to eliminate foreign microbes. 
IFN-γ, TNF-α, and IL-1β are critical mediators of an effective defense against Francisella 
infection (14, 15). SchuS4 suppresses pro-inflammatory cytokine induction in mouse lung 
resident DCs in early stages of the disease (13). Similarly, LVS dampens intracellular 
signaling and TNF-α in human monocytes and mouse macrophages (16). Administration of 
anti-IFN-γ, and anti-TNF-α antibodies greatly reduces the LD50 of LVS in an intradermal 
mouse model of mouse tularemia (17). IL-1β also is critical in innate defense against F. 
tularensis subsp. novicida (14). Disrupting the signaling pathway that leads to IL-1β 
processing greatly enhances host susceptibility to subsp. novicida infection.  
 IL-1β, one of the more potent pro-inflammatory cytokines, is tightly regulated by a 
two-step signaling process. The first step requires the transcriptional activation of pro-IL-1β 
followed by the translation of the pro-protein.  This is achieved by engagement of the toll-
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like receptors (TLR) and subsequent activation of MyD88-dependent signaling pathways, 
leading to NF-κB and MAP kinase induction. This leads to translocation of the NF-κB 
subunit p65 from the cytosol to the nucleus and activation of the MAP kinase 
phosphorylation cascade to cause the transcription of pro-IL-1β message. A second and 
separate signal is required after pro-IL-1β protein is produced, and this occurs in the cytosol, 
leading to the assembly of an inflammasome complex.  There are several types of 
inflammasomes, including those which contain an NLR (nucleotide binding domain-leucine 
rich repeats containing) component, and those which contain a non-NLR component, such as 
AIM2 (absent in melanoma 2) or RIG-I (retinoic acid-inducible gene 2) (18-22). Procaspase-
1 is a requisite member of the complex, while the adaptor PYCARD/ASC/TMS1 (Pyrin-
CARD, apoptotic speck-containing protein with a CARD, or target of methylation-induced 
silencing) is found in most inflammasome complexes (23, 24).  Upon inflammasome 
formation, procaspase-1 undergoes auto-catalytic cleavage into an active, mature form which 
subsequently cleaves pro-IL-1β and pro-IL-18 into their active forms. 
NLR family members share a conserved structure, with most of the members bearing 
an N-terminal Pyrin or CARD (caspase recruitment domain) domain followed by an NBD 
domain; and a C-terminal LRR domain that is homologous to those found in TLRs (25). A 
current working hypothesis is that, upon induction, the NLR recruits PYCARD via a Pyrin-
Pyrin homotypic interaction. PYCARD possesses its own CARD domain which recruits 
Caspase-1 into the inflammasome complex for IL-1β processing. Several NLRs that 
contribute to pathogen induced IL-1β release in macrophages have been identified (26). The 
absence of NLRs or their adaptors renders hosts more susceptible to a variety of pathogens. 
The NLRP3 inflammasome senses a wide variety of intracellular pathogens including Gram-
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positive and Gram-negative bacteria, RNA viruses, DNA viruses, yeast, microbial toxins and 
a host of damage-associated molecular patterns such as silica, asbestos and alum (27-29). 
The NLRC4/Ipaf inflammasome responds to bacterial virulence factors from the type III and 
IV secretion systems from bacteria such as Salmonella typhi, Burkholderia pseudomallei, 
Escherichia coli (30-32) and Pseudomonas aeruginosa (33).  
Unlike most Gram-negative bacterial pathogens, F. tularensis subspecies tularensis 
and holarctica do not provoke a substantial initial inflammatory response in vitro or in vivo 
(13, 33, 34).  F. tularensis LPS does not stimulate significant signaling through TLR4 (35), 
but this property alone does not account for the muted host response to infection.  The goal of 
this study was to identify mechanisms by which F. tularensis actively suppresses the host 
innate immune response.  To achieve this goal, we used an attenuated F. tularensis mutant 
that elicited a robust inflammatory response to reveal signaling pathways that are normally 
suppressed by wild type organisms and that dampen IL-1β, IL-18, and TNF-α responses to 
infection. 
 
MATERIALS AND METHODS 
Cell lines and Reagents 
Bone marrow derived macrophages were harvested from 6-8 week old mice and 
cultured for 7 days in 30% M-CSF conditioned media. THP-1 cells (ATCC) were cultured as 
described (36). Anti-IL-1β antibody was obtained from R&D Systems; anti-IκBα, phospho-
p65, phospho-ERK1/2, phospho-JNK, phospho-p38 from Cell Signaling; and anti-GAPDH 
from Santa Cruz Biotechnology. Detailed methods for preparation of retroviral shuttle 
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vectors, transduction and sorting to generate THP-1 cell lines stably expressing shRNA have 
been described (36). 
 
Western blotting and ELISA 
Western blots were performed as described (37, 38). Quantification of western blots 
by densitometry was performed using Adobe Photoshop. For ELISAs, mouse and human cell 
supernatants were collected 24 hours post-infection and assayed with BD OptEIA Mouse IL-
1β, IL-18, and TNF-α ELISA Sets (BD Biosciences). 
 
Cytotoxicity assays 
Cytotoxicity assays were performed using the ToxiLight® BioAssay kit (Lonza) 
following the manufacturer’s protocol for detection from supernatants. The luminescence 
was read using a TECAN Infinite M200 and analyzed using Magellan v6 software. 
 
Experimental Animals 
All studies were conducted in accordance with the National Institutes of Health 
Guidelines for the care and use of Laboratory Animals and the Institutional Animal Care and 
Use Committee guidelines of University of North Carolina, Chapel Hill. The generation of 
mice lacking functional Nlrp3, Nlrc4, Pycard, Caspase-1, and MyD88 has been previously 
described (38). C57BL/6 mice were purchased from Jackson Laboratories (Maine). 
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Bacteria Preparation 
F. tularensis LVS was obtained from the CDC, Atlanta, GA.  F. tularensis subsp. 
novicida U112 was obtained from ATCC. The LVS∆ripA strain has been described (12). All 
Francisella strains were maintained on chocolate agar supplemented with 1% IsoVitaleX 
(BD Biosciences) and grown in Chamberlain’s defined media (39). Other bacteria were 
grown in lysogeny broth (LB) medium or brain-heart infusion (BHI) medium. LVS and 
LVSΔripA were killed by incubation for 5 minutes at room temperature in 1 ml of 2% 
paraformaldehyde
 
in PBS, washed three times with PBS, and suspended in DMEM, 10% 
PBS. All cultures were grown at 37°C. 
 
Francisella infection of mouse primary macrophages and human monocytic cell lines 
LVS and LVS∆ripA were grown overnight in Chamberlain’s defined media prior to 
infection, and U112 was grown overnight on chocolate agar prior to infection. 
Concentrations of bacteria were determined by klett reading, and cells were exposed to the 
designated Francisella strain at the indicated MOI. Infected cells were incubated at 37
o
C and 
supernatants were harvested at select time points for cytokine analysis. For pharmacological 
assessments, cells were treated with Y-VAD-fmk (10 µM), U0126, SP-600125, and SB-
202190 (0.5 – 25 µM) as described (36). 
 
In vivo F. tularensis infection 
F. tularensis LVS from an overnight culture in Chamberlain’s media was centrifuged, 
and the pellet was suspended in PBS. These suspensions were enumerated by klett reading 
and diluted in Dubecco’s phosphate buffered saline (DPBS) for the inoculums. Wild-type 8- 
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to 10-week-old female C57BL/6 mice were anesthetized with avertin, as determined by 
insensitivity to a toe pinch, and were then infected intranasally with bacterial inoculums in a 
50 μl volume in DPBS. Mice were monitored for recovery from anesthesia. 
 
Statistical Analysis 
Statistical significance in Figures 1A-H, 2A-C, 3A-D, 5B-D was determined by two-
way analysis of variance (ANOVA) followed by a Tukey post-hoc test using Graph Pad 
Software (La Jolla, CA). Statistical significance in Figure 6 was determined by two-tailed 
Mann-Whitney U tests using Graph Pad Software (La Jolla, CA). The p values < 0.05 were 
considered statistically significant. Unless otherwise specified, data are presented as the 
mean ± standard deviation (s.d.). 
 
RESULTS 
F. tularensis LVSΔripA fails to suppress the release of pro-inflammatory cytokines IL-
1β, IL-18 and TNF-α by mouse primary macrophages. 
In response to foreign microbes, macrophages secrete pro-inflammatory cytokines 
including IL-1β, IL-18 and TNF-α which activate neutrophils, fibroblasts and endothelial 
cells to mount an anti-microbial response. F. tularensis can actively down-regulate host 
immune cytokine production in vivo and in vitro (7, 15). To assess the ability of F. tularensis 
to induce pro-inflammatory cytokines, we first compared the induction profile for the 
cytokine IL-1β in response to various bacterial pathogens in macrophages. We selected IL-1β 
due to its central role in initiating a variety of host immune defense cascades (40). When 
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compared to Salmonella typhi, Klebsiella pneumoniae and Shigella flexneri, mouse primary 
macrophages exposed to F. tularensis LVS released significantly less IL-1β (Figure 1A) 
suggesting that F. tularensis LVS represses this particular inflammatory response. One 
possible source of this difference is the LPS. LPS from S. typhi, K. pneumoniae, and S. 
flexneri may be more immune-stimulatory than F. tularensis LPS as described by another 
report (33).   
RipA (required for intracellular proliferation, factor A; FTL_1914) is a cytoplasmic 
membrane protein that is conserved among Francisella species and is required for adaptation 
of the bacteria to the host cell cytoplasm. Mutants lacking ripA (ΔripA strains) enter 
macrophages and escape from the phagosome at the same frequency and kinetics as wild type 
F. tularensis but fail to replicate intracellularly in the host cell (12). In that study, we 
demonstrated that LVSΔripA was unable to replicate intracellularly in host epithelial cells or 
macrophages. We considered that ΔripA strains might also be affected in their ability to 
suppress host cell immune responses. To test this possibility, we monitored IL-1β release by 
macrophages infected with wild type or LVSΔripA strains. Over a range of MOI, LVSΔripA 
induced roughly 5-10 fold higher levels of IL-1β, than wild type- infected macrophages 
(Figure 1B). Suppression of IL-1β was restored to LVSΔripA by in trans complementation 
with a ripA containing construct, pripA (Figure 1B), demonstrating a direct but inverse 
cause-and-effect relationship between F. tularensis RipA expression and IL-1β response. 
We next asked whether the effect of RipA on cytokine expression was widespread or 
limited to IL-1β. IL-18 production was measured since the inflammasome is also involved in 
processing and release of this cytokine. Increased levels of IL-18 similar to that of IL-1β 
were released by the LVSΔripA stimulated macrophages, and complementation reduced 
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induction nearly to wild type levels (Figure 1C). Since F. tularensis-induced TNF-α is not 
regulated by inflammasome components (14) but is regulated by MyD88 (35), we sought to 
test whether these findings hold true for LVSΔripA-induced TNF-α release. LVSΔripA 
induced 2-3 fold more TNF-α than wild type LVS (Figure 1D). The magnitude of the 
difference between LVS and LVSΔripA induced TNF-α release by macrophages was less 
than that of IL-1β. This suggests that ripA affects F. tularensis suppression of both 
inflammasome and non-inflammasome cytokines, but that the impact on inflammasome 
cytokines is more significant. Neither paraformaldehyde (PFA)-fixed wild type LVS or 
LVSΔripA mutant strains provoked significant levels of IL-1β (Figure 1E) demonstrating 
that the observed impact of RipA on cytokine expression was not due simply to lack of 
intracellular replication by the deletion mutant strain.  
One possible mechanism for the different levels of IL-1β induced by LVS versus 
LVSΔripA is that the former might cause more cell death, thus interfering with IL-1β 
production and processing. To assess cell viability differences between LVS and LVSΔripA, 
we measured cytotoxicity of primary mouse macrophages after infection with LVS, 
LVSΔripA, or the LVS ripA complementation strain. As shown in Figure 1F, infection with 
LVSΔripA resulted in increased cytotoxicity when compared to cells infected with wild type 
LVS or the ripA complementation strain. These data together suggest that LVSΔripA is both 
hyper-inflammatory and hyper-cytotoxic compared to wild type LVS. These results are 
consistent with the frequent association of inflammasome activation and cell death (41) as 
shown here for LVSΔripA, but inconsistent with the possibility that LVS causes more cell 
death which interferes with IL-1β production and release. 
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To further address the potential contribution of MOI to the observed phenotypes, 
primary mouse macrophages were exposed to wild type LVS at MOI 10, 50, or 500 and IL-
1β secretion was assayed by ELISA at 24 hours post infection. As shown in Figure 1G, IL-1β 
production increased with MOI; however, the levels of IL-1β produced at the lower MOI of 
10 was near the limit of detection. Therefore, for the subsequent LVS infections in primary 
mouse macrophages, MOI 50 or 500 was used.  
In contrast to the relatively low levels of IL-1 that we observe for wild type LVS, 
several studies have shown that infection with subsp. novicida result in high levels of IL-1β 
secretion and cell death, albeit the Mariathasan et al. study used LPS-pre-treated, 
thioglycolate-elicited peritoneal macrophages (14, 42). To determine if the differences in IL-
1β secretion are strain-specific, we infected resting BMDM with F. tularensis subsp. 
novicida U112 at MOI 10, 100, or 500 and assayed for IL-1β secretion at 24 hours post 
infection (Figure 1H). Similar to the results of Henry et al. (42) for subsp. novicida-induced 
IL-1β secretion in bone marrow-derived macrophages, our data shows that subsp. novicida 
strain U112 induced higher levels of IL-1β secretion by primary mouse macrophages (Figure 
1H).  
 
LVSΔripA-induced IL-1β is PYCARD, Caspase-1 and MyD88 dependent. 
In the regulation of IL-1β release by macrophages, bacterial-derived pathogen- or 
microbe-associated molecular patterns (PAMPs or MAMPs) first activate the TLR signaling 
pathway, thereby promoting the synthesis of pro-IL-1β transcript and later protein. A second 
signal initiates assembly of the inflammasome to process pro-IL-1β into IL-1β for release. To 
determine the level at which IL-1β release is regulated upon infection, we tested whether 
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disruption of either TLR or NLR/inflammasome signaling pathways can abrogate LVSΔripA 
induced IL-1β release. MyD88 was chosen for TLR signaling due to its central role in 
TLR/IL-1R pathways. To disrupt inflammasome formation, mice deficient in either Pycard 
or Caspase-1 were used since these two gene products are critical in subsp. novicida-induced 
IL-1β release by mouse macrophages and the ulceroglandular form of tularemia (14). 
Furthermore, two commonly interacting NLRs, NLRP3 and NLRC4 were tested because 
they are critical in the detection and response to several pathogens (26). In the absence of 
Pycard, Caspase-1 and MyD88, macrophages did not release IL-1β upon LVS or LVSΔripA 
exposure (Figure 2A). However, absence of Nlpr3 or Nlrc4 did not impair the LVSΔripA-
induced release of IL-1β suggesting that these NLRs are not involved in the sensing of F. 
tularensis. 
Similar to IL-1β release, PYCARD, Caspase-1, and MyD88 but not NLRP3 or 
NLRC4 were required for LVSΔripA induced IL-18 release by macrophages, further 
confirming effects on an additional inflammasome cytokine (Figure 2B).  As expected, 
MyD88 but not PYCARD, Caspase-1, NLRP3 or NLRC4 is required for LVSΔripA-induced 
release of the non-inflammasome cytokine TNF-α by primary mouse macrophages (Figure 
2C). Taken together, LVSΔripA induced IL-1β production is mediated by PYCARD, 
Caspase-1 and MyD88 which suggests that F. tularensis LVS may target the 
PYCARD/Caspase-1 axis as well as other TLR-dependent signaling pathways to suppress 
IL-1β release by macrophages. 
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F. tularensis LVSΔripA fails to suppress pro-inflammatory cytokine response by human 
monocytic THP-1 cells. 
To determine if the observed effects are also applicable to human cells, we measured 
cytokine expression by the human monocytic cell line, THP-1, in response to wild type LVS 
and LVSΔripA. THP-1 cells exposed to LVS∆ripA released 10-fold more IL-1β (Figure 3A) 
and 2-3 fold more TNF-α (Figure 3B) than cells exposed to wild type LVS, which is 
consistent with the mouse primary macrophage response. Also consistent, the difference in 
amount of TNF-α induced between LVS and LVSΔripA is of smaller magnitude than that of 
IL-1β. 
We next investigated whether PYCARD/ASC was required for LVS∆ripA induced 
IL-1β release by THP-1 cells using cells stably expressing either a control scramble 
PYCARD retroviral ShRNA vector (Sh-Ctrl) that does not confer knock down, a specific 
PYCARD retroviral ShRNA vector (Sh-PYCARD) to knock down PYCARD, or a specific 
NLRP3 retroviral ShRNA vector (Sh-NLRP3) to knock down NLRP3 (36). In our previous 
studies, all pathogens investigated induced IL-1β in a PYCARD dependent manner in a 
system where PYCARD expression was reduced by shRNA (36). Cells were infected with 
LVS and LVS∆ripA, and IL-1β was monitored. 24 hours post infection, Sh-PYCARD-
bearing THP-1 cells treated with either LVS or LVS∆ripA did not release detectable IL-1β 
(Figure 3C). In contrast, induction of IL-1β release was similar in sh-NLRP3-bearing cells 
and Sh-Ctrl-bearing cells. This is consistent with our studies using gene-deficient mouse 
primary macrophages. To determine whether caspase-1 is required for LVS∆ripA induced 
IL-1β release by THP-1 cells, THP-1 cells were pretreated with a specific Caspase-1 inhibitor 
(10 μM Y-VAD-fmk). Porphyromonas gingivalis, which induces a Caspase-1-dependent IL-
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1β release in THP-1 cells (37), served as control. Y-VAD blocked IL-1β release in response 
to infection with P. gingivalis, and also with LVS and LVSΔripA (Figure 3D). Based on this 
data, we concluded that PYCARD and Caspase-1 are required in LVSΔripA-induced IL-1β 
release by human monocytic THP-1 cells. 
 
F. tularensis LVSΔripA fails to suppress the processing and synthesis of IL-1β. 
To elucidate the mechanisms by which F. tularensis suppresses host macrophage 
release of pro-inflammatory cytokines, we first sought to determine kinetics of intracellular 
IL-1β synthesis and processing using western blot analysis to detect pro-IL-1β (33KD) and 
processed IL-1β (17KD) present in LVSΔripA-infected mouse macrophages over a time 
course following inoculation. Pro-IL-1β levels increased starting at 30 minutes post 
LVSΔripA exposure (Figure 4A), a time corresponding with the kinetics of phagosome 
escape by both wild type F. tularensis and LVSΔripA (12). IL-1β processing occurred 30-45 
minutes post infection, and processed IL-1β accumulated over several hours (Figure 4A). By 
24 hours post infection, the intracellular level of processed IL-1β decreased, likely due to 
release of IL-1β into the extracellular space and death of macrophages. To determine whether 
the response to LVS and LVSΔripA differs in the synthesis and processing of IL-1β by 
macrophages, we repeated a time course of infection. By 60 minutes, LVS induced the 
synthesis of pro-IL-1β, and no processed IL-1β was evident. Pro-IL-1β increased 
significantly 120 minutes post-inoculation with LVS; however, only a small fraction of the 
pro-protein was processed to mature IL-1β at this point as shown by western blotting for pro-
IL-1β and processed IL-1β (Figure 4B) and quantification of processed IL-1β by 
densitometry (Figure 4C). In contrast, pro-IL-1β was present in LVSΔripA-infected 
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macrophages by 60 minutes post infection, with the majority processed to mature IL-1β. Pro- 
IL-1β continued to increase by 120 minutes post-inoculation, with half of the pro-protein 
processed to mature IL-1β. 
Next, we sought to determine if F. tularensis LVS also disrupted of the synthesis of 
pro- IL-1β. To accomplish this objective, we exposed Pycard-/- mouse primary macrophages 
to LVS and LVSΔripA and monitored the synthesis of pro-IL-1β. Since the absence of 
PYCARD abolishes the processing of pro-IL1β into mature IL-1β, we can directly compare 
the macrophage synthesis of pro-IL-1β. In the absence of IL-1β processing, LVSΔripA-
infected macrophages induced significantly more pro-IL-1β than LVS as shown by western 
blot (Figure 4D) and quantified by densitometry in Figure 4E. Only pro-IL-1β is observed in 
LVS and LVSΔripA-infected Pycard-/- BMDM, because the absence of PYCARD prevents 
processing of IL-1β. Thus, F. tularensis LVS disrupts both the synthesis and processing of 
pro-IL-1β by macrophages. Collectively, these data suggest that the removal of RipA 
affected signaling pathways required for both the synthesis and processing of pro-IL-1β. 
The effect of RipA on both pro- IL-1β and TNF-α synthesis led us to test the effect of 
RipA on pathways that can affect the production of both cytokines. Since NF-κB is a master 
transcriptional regulator that controls a wide range of host immune responses, including 
cytokine production, we sought to determine if F. tularensis LVS interfered with NF-κB 
signaling in macrophages. Degradation of IκBα and phosphorylation of p65 were monitored 
because both events are involved in NF-κB activation. Degradation of IκBα allows 
phosphorylation and translocation of p65 into nucleus which subsequently binds to promoters 
of pro-inflammatory genes. LVS and LVSΔripA each induced degradation of IκBα 30-60 
minutes post infection, and phosphorylation of p-65 15-30 minutes post infection (Figure 
109 
 
4F). LVSΔripA appeared to induce slightly faster degradation of IκBα and phosphorylation 
of p65; however, these small differences alone are unlikely to account for the significant 
differences between LVSΔripA and LVS in the induction of TNF-α and pro-IL-1β.  
 
F. tularensis LVSΔripA fails to dampen the activation of MAP kinase pathways. 
Another common group of signaling pathways that contributes to cytokine activation 
by bacteria and bacterial components are the MAP kinase pathways. F. tularensis LVS 
initially activates MAP kinase signaling pathways but subsequently down-regulates their 
activity (43). To determine whether the difference between the cytokine activation by LVS 
and LVSΔripA might be explained by differences in the induction of MAP kinases, we 
profiled the phosphorylation of ERK1/2, JNK and p38 in macrophages following infection. 
LVS induced modest levels of ERK1/2 and p38 phosphorylation which peaked at 30 and 60 
minutes, but induced very little JNK activation (Figure 5A). In contrast, LVSΔripA induced 
dramatic levels of ERK1/2 phosphorylation at 15-30 minutes, and of JNK and p38 at 30-60 
minutes post inoculation. These data suggest that LVS dampened the induction of MAP 
kinase signaling pathways by a mechanism that is missing or ineffective in the ΔripA mutant 
strain. 
To determine whether differences in MAP kinase activation might explain the 
increased inflammatory nature of LVSΔripA, we abrogated MAP kinase activity in ΔripA 
infected cells with pharmacological inhibitors of ERK, JNK and p38 signaling pathways. 
Primary mouse macrophages were treated with U0126, SP-600125 or SB-202190 to prevent 
the phosphorylation of ERK1/2, JNK and p38, respectively. These cells were subsequently 
exposed to either LVS or LVSΔripA, and IL-1β release was measured 24 hours post 
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infection. Both U0126 and SP-600125 reduced the release of IL-1β by macrophages by 1.5-2 
fold following infection with LVSΔripA over a range of doses (Figure 5B). Thus, ERK and 
JNK pathways each partially contribute to IL-1β activation in ΔripA-infected cells. The 
addition of U0126 or SP-600125 also reduced the release of TNF-α by macrophages upon 
exposure to LVS and LVSΔripA (Figure 5C). Finally, the combination of ERK, JNK and p38 
inhibitors blocked LVSΔripA-induced IL-1β release by macrophages more effectively than 
each inhibitor alone (Figure 5D). Taken together, these data demonstrate that wild type F. 
tularensis LVS interferes with the activation of multiple MAP kinase signaling pathways that 
are important for release of cytokines following infection.  
 
F. tularensis LVSΔripA fails to suppress pro-inflammatory cytokine responses in vivo. 
Our previous study showed that LVSΔripA is attenuated in mice as evidenced by a 
reduction in organ burden at days 1, 3 and 7 post intranasal infection when compared to LVS 
(12). In this study we confirm and expand this finding by monitoring mice morbidity, 
mortality and cytokine responses post infection. Mice were intranasally inoculated with LVS, 
LVSΔripA and mock/PBS, and weight loss was monitored among the three experimental 
groups. When using a LD100 dose of LVS (10
5
), LVS-inoculated animals exhibited severe 
weight loss, a measure of the severity of respiratory tularemia, and eventually succumbed to 
the disease (Figure 6A). In contrast, LVSΔripA-inoculated animals only showed a modest 
weight loss when compared to mock/PBS treated animals. We also measured the bacterial 
burdens in the lungs of mice during the early stages of the disease (6 and 24 hours post 
infection). Similar lung burdens were observed 6 hours post infection when comparing LVS 
and LVSΔripA, indicating that the initial bacterial loads of LVS and LVSΔripA are 
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indistinguishable (Figure 6B). By 24 hours post inoculation, LVS lung burdens rose to 10
6
 
CFU/organ. In contrast, the lung burden of LVSΔripA inoculated animals did not increase 
beyond that of the 6 hour time point. In our previous report, the ripA complementation strain 
of LVSΔripA inoculated animals exhibited similar lung, spleen, and liver burdens when 
compared to LVS inoculated animals (12).  
The in vitro analyses shown earlier indicate that LVSΔripA failed to suppress the 
release of IL-1β, IL-18 and TNF-α by primary mouse macrophages and human THP-1 cells. 
To determine if the absence of ripA similarly affected cytokine responses in vivo, we 
measured IL-1β and TNF-α in the lungs of infected mice. After testing multiple doses of 
LVS∆ripA to determine the amount required to detect IL-1β and TNF-α in the lung (Figure 
6C), we found that mice inoculated with 10
10
 CFU of LVS∆ripA expressed on average 5-10 
fold more IL-1β than animals inoculated with the same number of wild type LVS (Figure 
6D). Interestingly, at that dose of bacteria, IL-1 levels in the BALF of animals infected with 
wild type LVS was indistinguishable from mock/PBS-treated mice. We next examined levels 
of TNF-α in mouse lungs of mock/PBS, LVS and LVS∆ripA-inoculated animals. LVS∆ripA 
induced more TNF-α than LVS, but the difference was not as significant as that of IL-1β 
(Figure 6E). These results are consistent with the in vitro results obtained with mouse and 
human cells (Figures 1D, 3B) and support the effects of ripA deletion on both inflammasome 
and non-inflammasome mediated cytokines. Taken together, these data suggest that the 
expression of ripA in LVS suppresses macrophage pro-inflammatory cytokine production 
during an infection both in vitro and in vivo. 
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DISCUSSION 
 The innate immune response is indispensible to eradicate the invasion of microbial 
pathogens, and monocytes/macrophages are major arsenals in combating infectious diseases. 
Proper release of cytokines and chemokines by these cells is critical in the migration of 
polymorphonuclear (PMN) cells and other effector cells to the site of infection. To establish 
a successful infection, a pathogen must either evade immune surveillance or modulate host 
anti-microbial response. Over time, pathogens have developed sophisticated strategies to 
manipulate host immune responses to their advantage. In this study, we demonstrated that F. 
tularensis actively suppresses the release of pro-inflammatory cytokines, and that the F. 
tularensis gene ripA is critical in this process. In response to F. tularensis LVSΔripA, 
macrophages are able to mount an effective initial response by releasing higher amounts of 
IL-1β, IL-18 and TNF-α when compared to LVS. This observation is also seen in vivo, which 
correlates with the reduced morbidity caused by LVSΔripA. These data suggest that ripA 
contributes to effective suppression of host immunity, and hence F. tularensis survival. Of 
equal importance is the role of IFN-γ and IFN-β during host response to F. tularensis, and it 
would be interesting to test whether the IFN-β and IFN-γ responses are altered in LVS∆ripA-
treated cells and animals during an infection. 
An emerging theme in the literature is that a variety of pathogens can suppress IL-1β 
release by macrophages. Pseudomonas aeruginosa induces the release of IL-1β by 
macrophages in a NLRC4 dependent manner (32). A subset of P. aeruginosa expresses the 
effector molecule ExoU, and this molecule inhibits Caspase-1 activation thereby preventing 
the release IL-1β and IL-18 by macrophages. Mycobacterium tuberculosis (Mtb) circumvents 
both innate and adaptive immune responses. Similar to our observations with F. tularensis, 
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the Mtb gene product zmp1 prevents the activation of the inflammasome to inhibit IL-1β 
processing (44). Among viruses, Myxoma virus (MYXV) inhibits release of pro-
inflammatory cytokines IL-1β, IL-18, TNF-α, IL-6 and MCP-1. MYXV encodes a pyrin 
containing protein m103 which has been shown to bind to PYCARD and thereby disrupt the 
activation of inflammasome (45). The m103 protein also binds NF-κB which suppresses the 
degradation of IκBα and phosphorylation of IKK. Cowpox virus, via gene crmA, directly 
inhibits Caspase-1 activity, and suppresses IL-1β response to infection (46). Our study with 
F. tularensis LVS and LVSΔripA together with these and other reports exemplifies the 
multiple strategies employed by pathogens to disrupt host immune activation of the 
production of IL-1β and other cytokines by innate immune cells. 
 To elucidate the pathways by which LVS suppresses the IL-1β release by 
macrophages, we have identified PYCARD, Caspase-1 and MyD88 mediated signaling that 
the LVS strain can disrupt. Mariathasan and coworkers have shown that PYCARD and 
Caspase-1 mediated host IL-1β production is key in combating subsp. novicida infection 
(14). In their study, mice lacking Pycard or Caspase-1 were far more susceptible to challenge 
by F. tularensis subsp. novicida. Moreover, mice intraperitoneally injected with IL-18 and 
IL-1β neutralization antibody prior to subsp. novicida challenge exhibited higher organ 
burdens than those treated with isotype control, further suggesting the importance of IL-1β 
and IL-18 in tularemia. Recently, AIM2 has been identified as candidate proteins required in 
F. tularensis induced inflammasome formation and subsequent IL-1β release (19, 47, 48). 
Thus far, TLR2, MyD88 and type I Interferon β have been implicated in F. tularensis 
induced host cytokine response, including IL-1β by macrophages (14, 35, 49-51). Our data 
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suggest that F. tularensis LVSΔripA induced IL-1β is PYCARD, Caspase-1 and MyD88 
dependent and that LVS disrupts these signaling pathways. 
 In macrophages and epithelial cells, PAMPs or MAMPs activate NF-κB and MAP 
kinase pathways to initiate the pro-inflammatory responses. There are three major families of 
MAP kinase including the extracellular signal-regulated protein kinases (ERK), the c-Jun 
NH2-terminal kinases (JNK) and the p38 kinases (52). Many pathogens have developed 
strategies to disrupt the MAP kinase pathway to subvert the immune response. Arbibe and 
coworkers demonstrated that Shigella flexneri virulence factor OspF inactivates ERK1/2 and 
p38 by preventing their phosphorylation (53). YopJ, a type III effector protein of Yersinia 
species has been shown to acetylate the serine and threonine residues on MAP kinase kinase 
(MAPKK) thereby interrupting the downstream MAP kinase phosphorylation (54). Telepnev 
and coworkers have demonstrated that LVS may interfere with MAP kinase signaling 
pathways and that iglC is critical in this process (43). Our data suggest that LVS may be able 
to interfere with both the synthesis and processing of IL-1β at multiple points and that ripA is 
critical in these processes. The degradation of IκBα and phosphorylation of p65 is not likely 
the major mechanism by which ripA mediates immune suppression. However, LVSΔripA 
induced a significant increase in phosphorylation of these three MAP kinases when compared 
to wild-type LVS. Moreover, our studies showed that the LVSΔripA induced IL-1β and 
TNF-α release can be partially reduced by pre-treating cells with inhibitors of ERK, JNK and 
p38 alone, while the use of all three inhibitors resulted in an additive reduction of cytokine 
production that approaches the lower level caused by LVS infection. These results further 
validate that ripA contributes to the MAP kinase suppressive nature of F. tularensis. LVS 
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synergistically down-regulates the synthesis of pro-IL1β, and prevents the processing of IL-
1β, thereby resulting in strong suppression of IL-1β release by macrophages. 
 A specific function for RipA protein has not yet been identified. Our experiments 
using PFA-killed LVS and LVS∆ripA demonstrated that RipA-mediated suppression of the 
induction of IL-1β by LVS-infected host cells is an active process. In other words, the 
induction is not solely the result of gross morphological change in the bacterial cell or a cell 
surface marker that is present in LVS∆ripA regardless of the bacterial viability. Preliminary 
data from our lab also indicates that the outer membrane profile and LPS profile of 
LVS∆ripA is unchanged. Furthermore, our previous study demonstrated that RipA is 
localized to the cytoplasmic membrane of F. tularensis (12). This finding suggests that RipA 
does not mediate immune response suppression by directly interfering with or binding to 
innate immune receptors or sensors. More likely RipA is interacting with another protein or 
proteins that interfere with the pro-inflammatory signaling pathways.   
Others have also found that infection of macrophages with LVS blocks TLR-induced 
signaling (43); however, there are seemingly conflicting reports that F. tularensis subsp. 
novicida or LVS is a potent inducer of pro-inflammatory cytokines (14, 33, 55, 56). These 
apparent contradictions may be due to variations in the experimental designs, such as the 
differences in MOI, the activation state of the cell population used, or the different 
subspecies used. Ulland et al. reported nanogram levels of IL-1β secretion from LPS-pre-
stimulated BMDM that were subsequently infected with LVS (56), whereas we infected 
naïve BMDM. We also have found that following pre-stimulation of BMDM cells with E. 
coli LPS, LVS induced high levels of IL-1β (data not shown). Thus, the activation state of 
the cell likely affects the cytokine levels produced in response to F. tularensis. Consistent 
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with this possibility, Cole et al (55) found substantial LVS-induced IL-1 response by 
thioglycolate-elicited peritoneal macrophages.  We believe that the use of non-stimulated 
macrophages, as in our study, might better reflect the host response during a primary 
infection.  
An additional difference between our study and the latter is that our study primarily 
used LVS at MOIs of 50 to 500, while the paper by Cole and colleagues used MOI of 5-10 
(55).  We found that infection of resting macrophages with a low MOI of LVS induced little 
IL-1and the increased MOI is therefore unlikely to explain the difference in cytokine 
induction levels. Furthermore, the fact that LVSΔripA is both hyper-inflammatory and hyper-
cytotoxic compared to wild type LVS, suggests that differences in cell death induction in 
LVS cannot explain the differences in IL-1 production and release (Fig. 1F). Finally, it is 
possible that these differences are due to infection by different subspecies. F. tularensis 
subsp. novicida, a less virulent subspecies, caused substantial IL-1β and IL-18 production 
and caspase-1-dependent cell death at the low MOI (14). Likewise, we found that a similar 
range of doses of subsp. novicida U112 caused a significant amount of IL-1 release in 
resting BMDM (Fig. 1H) whereas LVS did not (Fig. 1G).  This suggests that the high levels 
of IL-1 in other studies relative to ours might also be explained by the use of different F. 
tularensis subspecies. While we acknowledge that LVS may induce various levels of 
cytokines depending on the methods of preparing primary mouse macrophages, it is clear that 
the deletion of ripA alleviated the immuno-suppressive nature of LVS with respect to IL-1β 
and TNF-α.  
In conclusion, we elucidated a mechanism by which F. tularensis actively evades host 
immune response by an analysis of the attenuated LVSΔripA strain. These results indicate 
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that the ripA gene product functions by targeting two prominent innate immune circuits: the 
circumvention of the host inflammasome response and the dampening of the activation of 
MAP kinase signaling pathways.  During the review of this paper, there was a report of 
another immune evasion gene in LVS that when removed, resulted in elevated IL-1 and cell 
death accompanied by reduced in vivo bacterial replication (56). Thus, the phenomenon 
described herein might be a common pathway for immune evasion by F. tularensis. 
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FIGURES 
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Figure 1. F. tularensis LVSΔripA fails to suppress pro-inflammatory cytokine release by 
primary mouse macrophages. (A) IL-1β secretion levels in mouse macrophages following 
exposure to F. tularensis LVS, Salmonella typhi, Klebsiella pneumoniae, or Shigella flexneri 
at MOI 50 for 24 hours as determined by ELISA. Data represent mean ± s.d. for at least three 
independent experiments performed in triplicate. A representative experiment is shown. *, p 
< 0.05 (B) IL-1β secretion levels in mouse macrophages exposed to LVS, LVSΔripA, or 
LVSΔripA complementation strain at MOI 50 and 500 for 24 hours. Data represent mean ± 
s.d. for at least three independent experiments performed in triplicate. A representative 
experiment is shown. *, p < 0.05 (C) IL-18 secretion levels in mouse macrophages exposed 
to LVS, LVSΔripA, or LVSΔripA complementation strain at MOI 50 and 500 for 24 hours. 
Data represent mean ± s.d. for at least three independent experiments performed in triplicate.  
A representative experiment is shown. *, p < 0.05 (D) TNF-α secretion levels in mouse 
macrophages exposed to LVS, LVSΔripA, or LVSΔripA complementation strain at MOI 50 
and 500 for 24 hours. Data represent mean ± s.d. for at least three independent experiments 
performed in triplicate. A representative experiment is shown. *, p < 0.05 (E) IL-1β secretion 
levels in mouse macrophages exposed to live and PFA-treated LVS and LVSΔripA at MOI 
50 and 500 for 24 hours. Data represent mean ± s.d. for at least three independent 
experiments performed in triplicate. A representative experiment is shown. *, p < 0.05 (F) 
Cytotoxicity of mouse macrophages exposed to LVS, LVSΔripA, or LVSΔripA 
complementation strain at MOI 500 for 24 hours as measured by luminescence.  Data 
represent mean± s.d. for at least three independent experiments performed in duplicate or 
triplicate. A representative experiment is shown. *, p < 0.05 (G) IL-1β secretion levels in 
mouse macrophages exposed to LVS at MOIs 10, 50, 500 for 24 hours. Data represent mean 
± s.d. for at least three independent experiments performed in triplicate. A representative 
experiment is shown. (H) IL-1β secretion levels in mouse macrophages exposed to U112 at 
MOIs 10, 100, 500 for 24 hours. Data represent mean ± s.d. for at least three independent 
experiments performed in triplicate. A representative experiment is shown. 
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Figure 2. LVSΔripA induced pro-inflammatory cytokines are regulated by 
inflammasome components and MyD88. (A) IL-1β secretion levels in mouse macrophages 
derived from Wt, Pycard
-/-
, Caspase-1
-/-
, MyD88
-/-
, Nlrp3
-/-
, and Nlrc4
-/-
 mice exposed to 
LVS and LVSΔripA at MOI 500 for 24 hours as assessed by ELISA of cell supernatants. 
Data represent mean ± s.d. for at least three independent experiments performed in triplicate. 
A representative experiment is shown. *, p < 0.05 (B) IL-18 secretion levels in macrophages 
derived from Wt, Pycard
-/-
, Caspase-1
-/-
, MyD88
-/-
, Nlrp3
-/-
, and Nlrc4
-/-
 mice exposed to 
LVS and LVSΔripA at MOI 500 for 24 hours. Data represent mean ± s.d. for at least three 
independent experiments performed in triplicate. A representative experiment is shown. *, p 
< 0.05 (C) TNF-α secretion levels in mouse macrophages derived from Wt, Pycard-/-, 
Caspase-1
-/-
, MyD88
-/-
, Nlrp3
-/-
, Nlrc4
-/-
 exposed to LVS and LVSΔripA at MOI 500 for 24 
hours. Data represent mean ± s.d. for at least three independent experiments performed in 
triplicate. A representative experiment is shown. *, p < 0.05 
 
121 
 
 
 
Figure 3. LVS ripA is necessary for suppression of pro-inflammatory cytokine release 
by human THP-1 cells. (A) IL-1β secretion levels in THP-1 cells exposed to LVS and 
LVSΔripA at MOI 500 for 24 hours. Data represent mean ± s.d. for at least three independent 
experiments performed in triplicate. A representative experiment is shown. *, p < 0.05 (B) 
TNF-α secretion levels in THP-1 cells exposed to LVS and LVSΔripA at MOI 500 for 24 
hours. Data represent mean ± s.d. for at least three independent experiments performed in 
triplicate. A representative experiment is shown. *, p < 0.05 (C) IL-1β secretion levels in 
THP-1 cells expressing stable Sh-Ctrl, Sh-PYCARD and Sh-NLRP3 exposed to LVS and 
LVSΔripA at MOI 500 for 24 hours. Data represent mean ± s.d. for at least three independent 
experiments performed in triplicate. A representative experiment is shown. *, p < 0.05 (D) 
IL-1β secretion levels in mock pre-treated THP-1 cells and cells pre-treated with Y-VAD and 
exposed to LVS and LVSΔripA at MOI 500 for 24 hours. Data represent mean ± s.d. for at 
least three independent experiments performed in triplicate.  A representative experiment is 
shown. *, p < 0.05  
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Figure 4. F. tularensis LVS suppresses IL-1β response in macrophages by interfering 
with IL-1β synthesis and processing. (A) Western blot analysis of IL-1β expression in 
mouse macrophages exposed to LVSΔripA at MOI 500 for 0, 5, 15, 20, 30, 45, 60, 120, 180 
minutes and 24 hours. At least three independent experiments were performed. A 
representative western blot is shown. (B) Western blot analysis of IL-1β expression in mouse 
macrophages exposed to LVS and LVSΔripA at MOI 500 for 0, 15, 30, 60 and 120 minutes. 
At least three independent experiments were performed. A representative western blot is 
shown. (C) Densitometric quantification of the bands for processed IL-1β (17KD) is shown 
in B. (D) Western blot analysis of IL-1β expression in macrophages derived from Pycard-/- 
mice following exposure to LVS and LVSΔripA at MOI 500 for 0, 30, 60 and 120 minutes. 
At least three independent experiments were performed. A representative western blot is 
shown. (E) Densitometric quantification of the bands for pro-IL-1β (33KD) shown in D. F. 
Western blot analysis of IκBα and phospho-p65 in mouse macrophages exposed to LVS and 
LVSΔripA at MOI 500 for 0, 15, 30 and 60 minutes. At least three independent experiments 
were performed. A representative western blot is shown. 
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Figure 5. F. tularensis LVS suppresses pro-inflammatory cytokine release by disrupting 
MAP kinase signaling pathways. (A) Western blot analysis of phospho-ERK1/2, phospho-
JNK, phospho-p38 and GAPDH in mouse macrophages exposed to LVS and LVSΔripA at 
MOI 500 for 0, 15, 30 and 60 minutes. At least three independent experiments were 
performed. A representative western blot is shown. (B) IL-1β secretion levels in mouse 
macrophages pre-treated with ERK inhibitor U0126 and JNK inhibitor SP-600125 and 
exposed to LVS and LVSΔripA at MOI 500 for 24 hours. Data represent mean ± s.d. for at 
least three independent experiments performed in triplicate. A representative experiment is 
shown. *, p < 0.05. (C) TNF-α secretion levels in mouse macrophages pre-treated with 
U0126 or SP-600125 and exposed to LVS or LVSΔripA at MOI for 24 hours. Data represent 
mean ± s.d. for at least three independent experiments performed in triplicate. A 
representative experiment is shown. *, p < 0.05 (D) IL-1β secretion levels in mouse 
macrophages pre-treated with, U0126, SP-600125, p38 inhibitor SB-202190 or a 
combination of U0126, SP-600125 and SB-202190 and exposed to LVS or LVSΔripA at 
MOI 500 for 24 hours. Data represent mean ± s.d. for at least three independent experiments 
performed in triplicate. A representative experiment is shown. *, p < 0.05 
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Figure 6. LVSΔripA fails to suppress pro-inflammatory cytokine responses in a mouse 
respiratory tularemia model. (A) Body weights of mice intranasally (i.n.) exposed to mock, 
LVS and LVSΔripA at dose of 105 for 1-10 days. At least two independent experiments with 
7 animals per experimental condition (PBS, LVS, and LVSΔripA) were performed. A 
representative experiment is shown. (B) Lung organ burdens of mice i.n. exposed to LVS and 
LVSΔripA at a dose of 105 for 6 and 24 hours. At least three in, p ndent experiments with 
more than 4 animals per group were performed. Each symbol represents one animal. A 
representative experiment is shown. (C) IL-1β levels in mouse bronchoalveolar lavage fluid 
(BALF) following i.n. exposure to LVSΔripA at increasing doses for 24 hours. Data 
represent mean ± s.d. for at least two independent experiments with more than 3 animals per 
group. Each symbol represents one animal. A representative experiment is shown. (D) IL-1β 
levels in mouse BALF following mock treatment or i.n. exposure to LVS or LVSΔripA (1010 
bacteria per animal for both LVS and LVSΔripA) for 24 hours. Data represent mean ± s.d. 
for at three independent experiments with more than 6 animals per group. Each symbol 
represents one animal. All data are shown. *, p < 0.05 (E) TNF-α levels in mouse BALF 
following mock treatment or i.n. exposure LVS or LVSΔripA (1010 bacteria per animal for 
both LVS and LVSΔripA) for 24 hours. Data represent mean ± s.d. for at least three two 
independent experiments with more than 6 animals per group. Each symbol represents one 
animal. All data are shown. 
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ABSTRACT 
 Francisella tularensis is a Gram-negative coccobacillus and is the etiological agent of 
the disease tularemia. Expression of the cytoplasmic membrane protein RipA is required for 
Francisella replication within macrophages and other cell types; however, the function of 
this protein remains unknown. RipA is conserved among all sequenced Francisella species, 
and RipA-like proteins are present in a number of individual strains of a wide variety of 
species scattered throughout the prokaryotic kingdom. Crosslinking studies revealed that 
RipA forms homoligomers. Using a panel of RipA-GFP and RipA-PhoA fusion constructs, 
we determined that RipA has a unique topology within the cytoplasmic membrane with the 
N- and C- termini in the cytoplasm and periplasm, respectively. RipA has two significant 
cytoplasmic domains, one comprised roughly of amino acids 1 – 50, and the second flanked 
by the second and third transmembrane domains and comprising amino acids 104 – 152. 
RipA functional domains were identified by measuring the effects of deletion mutations, 
amino acid substitution mutations and spontaneously arising intragenic suppressor mutations 
on intracellular replication, induction of IL-1β secretion by infected macrophages, and 
oligomer formation.  Result from these experiments demonstrated that each of the 
cytoplasmic domains and specific amino acids within these domains were required for RipA 
function. 
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INTRODUCTION 
 Francisella tularensis is a Gram-negative coccobacillus that is the etiological agent of 
the zoonotic disease tularemia. F. tularensis infects a wide range of hosts, which includes 
humans, but predominately infects small mammals such as rabbits, voles, and squirrels (24). 
F. tularensis has also been isolated from arthropod vectors such as ticks (29, 34), mosquitoes 
(28, 43), and deerflies (24), which are also a source of transmission to humans (5, 6). 
Additional modes of transmission to humans include contact with infected animals (30, 31, 
36), ingestion of contaminated food or water (23, 25), and inhalation of aerosolized bacteria 
(37, 42). There are four main subspecies of F. tularensis that differ in their virulence for 
humans: novicida, mediasiatica, holarctica, and tularensis. Subspecies novicida is not 
generally considered pathogenic for humans; however, there have been a few cases reported 
(1, 9, 20, 26). Subspecies mediasiatica is also associated with human disease in Asia, though 
less is understood about its pathogenesis (24). Subspecies holarctica and tularensis are most 
commonly associated with disease in humans with the latter being associated with the lowest 
infectious dose and most severe disease. For subspecies tularensis, transmission to humans 
via the inhalational route can occur at an infectious dose of as few as ten organisms (35). The 
ease of aerosolization and low infectious dose resulted in the designation of F. tularensis 
subspecies tularensis a select agent by the Centers for Disease Control, especially 
considering the historical development of F. tularensis bioweapons by several countries 
during the Cold War (13).  
 Within the lung, F. tularensis travels to the alveoli where it infects a wide range of 
cell types including alveolar macrophages, neutrophils, dendritic cells, monocytes, and 
alveolar Type II epithelial cells (2, 18, 19). F. tularensis is taken up by host cells via looping 
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phagocytosis, and after internalization, the bacteria escape the phagosome to replicate to high 
numbers in the cytoplasm (10, 11). In addition to the ability to replicate intracellularly, F. 
tularensis is able to suppress the pro-inflammatory immune response (2, 3, 8, 22, 40, 41). 
Several F. tularensis proteins have been reported as virulence factors that are required for 
this intracellular lifecycle; however, many of the identified virulence factors have little or no 
similarity to known proteins of other bacteria and their functions remain, for the most part, 
unknown. 
 Previously we identified a locus called ripA that is required for F. tularensis 
virulence. More specifically, deletion of this locus in the live vaccine strain (LVS) resulted in 
a mutant (LVS∆ripA) that escapes the phagosome but is defective for intracellular replication 
(17) and fails to suppress the pro-inflammatory immune response (22). Not surprisingly, 
LVS∆ripA is also attenuated in a pulmonary mouse model of tularemia (17). Deletion of ripA 
in the highly virulent F. tularensis Schu S4 strain results in a mutant that is defective for 
intracellular replication and attenuated in a mouse model as well, suggesting that RipA is 
required for virulence in the highly pathogenic F. tularensis subspecies tularensis (our 
unpublished results). 
 RipA is a cytoplasmic membrane protein that is conserved among Francisella species 
(17). Interestingly, bioinformatic analyses by our lab show that there is sporadic 
representation of RipA-like proteins among Prokaryotes, where RipA-like proteins are found 
in only specific strains of a given bacterial species. Similar to RipA, these other proteins are 
annotated as hypothetical proteins with no known functions or conserved domains; thus, the 
function of RipA remains unknown. RipA is a small protein (17 kD) with three 
transmembrane domains and has a single cysteine found within the second membrane-
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spanning domain, which are unusual properties for a membrane protein, and examples of 
similar proteins in the literature are sparse. The unusual biochemical properties, combined 
with RipA’s random distribution but obvious conservation within Prokaryotes, led us to 
study RipA for its potential for providing insight into what may be a novel class of proteins 
and/or for revealing a novel virulence mechanism employed by F. tularensis.   
 In this report, we address the question of RipA function by analyzing RipA at the 
biochemical and molecular level. Our results confirm a predicted topology model of RipA in 
the cytoplasmic membrane and show that RipA forms homoligomers. Using the topology 
model and alignments to other RipA-like proteins, amino acid substitutions were generated at 
conserved amino acids and the two individual cytoplasmic domains were deleted within 
RipA. These amino acid substitution and domain deletion mutants were analyzed for their 
ability to replicate intracellularly, suppress the immune response, and to form RipA 
oligomers. We also identified and analyzed an intragenic suppressor mutant. Using the 
suppressor mutant as well as the substitution and deletion mutants of RipA, we showed that 
both cytoplasmic domains and at least four amino acids are required for RipA function. 
 
MATERIALS AND METHODS 
Bacterial strains.  
 Francisella tularensis subsp. holarctica live vaccine strain (LVS) was obtained from 
the CDC, Atlanta, GA. All Francisella strains were maintained on chocolate agar 
supplemented with 1% IsoVitaleX (Becton-Dickson) and when applicable, 10 μg ml-1 
kanamycin (Kan10) for selection. For growth of bacteria for infection or monitoring in vitro 
growth, strains were propagated in Chamberlain’s defined medium (7).  Escherichia coli 
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TOP10 (Invitrogen) or DH10b (Invitrogen) were used for cloning purposes. E. coli CC118 or 
BL21 (DE3)pLysS were used for expression of topology fusion reporter proteins.  E. coli was 
propagated in Luria broth supplemented with ampicillin at 100 μg ml-1 (Amp100) or 
kanamycin at 50 μg ml-1 (Kan50) as necessary for antibiotic selection.  All cultures were 
grown at 37°C with aeration. 
 
Cell culture.  
 TC-1 (ATCC CRL-2785) cells are a tumor cell line derived from mouse primary lung 
epithelial cells and were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 
2 mM L-glutamine, 1.5 g L
-1
 sodium bicarbonate, 10 mM HEPES and 0.1 mM nonessential 
amino acids.  J774A.1 (ATCC TIB-67) cells are a macrophage-like cell line derived from 
mouse sarcoma reticulum cells and were cultured in Dulbecco’s minimal essential medium 
with 4.5 L
-1
 glucose, 10% fetal bovine serum, and 2 mM L-glutamine. Bone marrow-derived 
macrophages were generated by flushing C57BL/6 mouse femurs and recovered cells were 
incubated for 6 days on 15 cm
2
 non-tissue culture-treated dishes in L929 cell-conditioned 
DMEM. Nonadherent cells were removed by washing with phosphate-buffered saline (PBS) 
and bone marrow-derived macrophages were recovered from the dish using 10 mM EDTA in 
PBS. For experiments, BMMs were maintained in DMEM plus 10% FBS.  
 
Molecular techniques and mutagenesis.  
 To generate constructs for RipA fusion protein expression, using the Phusion 
polymerase (New England Biosciences) we PCR-amplified ripA from LVS genomic DNA 
using primers that introduced XhoI and BamHI restriction sites directly before the start 
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codon and in place of the stop codon of ripA, respectively. For cloning of truncated ripA 
constructs, the reverse primer introduced a BamHI restriction site at the respective locations 
in ripA sequence but used the same forward primer. These constructs were first cloned into 
the pCR-Blunt II TOPO vector (Invitrogen) and subsequently subcloned using BamHI and 
XhoI restriction digest and ligation into pWaldo-TEV-GFPe and pHA-4 (33) to generate the 
fusion protein expression constructs. For expression of fusion proteins, the plasmids were 
transformed into E. coli CC118 (pHA-4) or E. coli BL21 (DE3)pLysS (pGFPe) by 
electroporation with selection on ampicillin at 100 μg ml-1 (pHA-4) or kanamycin at 50 μg 
ml
-1
 (pGFPe). 
 The cytoplasmic loop deletions in ripA were generated by gene synthesis of ripA 
containing the designated nucleotide deletions (corresponding to amino acids 4-47 or 105-
151) and linker sequence insertion while maintaining the integrity of the flanking regions 
(Blue Heron). Each construct was PCR-amplified from the synthesis vector and cloned into 
the pCR-Blunt II TOPO vector (Invitrogen), verified by DNA sequence analysis, and 
subsequently subcloned into pMP590 (sacB Kan
r
) using the BamHI and NotI restriction sites 
(27). For allelic exchange, plasmids were electroporated into LVS and integrants were 
selected on chocolate agar containing kanamycin (10 μg ml-1).  Kanr strains were grown 
overnight and plated on 10% sucrose for counterselection (loss of plasmid) (17). Deletions 
were confirmed by PCR analysis of genomic DNA using primers external to deleted regions. 
The strategy for generation of the ripA deletion in LVS and for complementation of the ripA 
deletion has been described (17).   
 Single amino acid changes in RipA were generated by introducing 1-2 bp changes in 
the respective codon of the ripA DNA sequence using QuikChange II Site-directed 
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Mutagenesis kit (Stratagene) following the manufacturer’s protocol. The plasmid used for 
mutagenesis was the multi-copy Francisella shuttle vector pKKMCS that expressed ripA 
under its native promoter and containing both 5’ and 3’ flanking regions. After DNA 
sequence confirmation of the mutations within ripA, the plasmids were each transformed into 
the LVS∆ripA strain by electroporation and selection on chocolate agar Kan10. 
 To generate HA-tagged ripA, a fusion construct was made by splice overlap extension 
(21) with primers that introduced the HA tag in-frame to the C-terminus of the coding 
sequence of ripA and including a glycine linker sequence between the end of the coding 
sequence and the HA tag. This construct was sequenced before use and then cloned into 
pMP590 suicide vector and used for allelic exchange to generate a chromosomally-expressed 
HA-tagged protein. Clones were screened using one primer specific to the tag and the second 
specific to sequence on the chromosome. Additionally, this same construct was cloned into 
pKKMCS to generate a plasmid-expressed HA-tagged protein. Integrity of the sequence was 
confirmed by DNA sequence analysis.  
 
GFP fluorescence and alkaline phosphatase activity assays.  
 Procedures for protein expression, GFP fluorescence and PhoA activity were adapted 
from published protocols (12, 15, 33). For expression of the GFP fusion proteins, E. coli 
BL21(DE3)pLysS containing each construct was grown in 1ml LB Kan50 overnight at 37°C 
and then diluted 1:50 into 500 μl LB Kan50 per well of a 48-well plate and grown at 37°C, 
250 rpm to OD600= 0.3-0.4. Expression was then induced by addition of 0.4 mM IPTG and 
growth to a final OD600=0.6-0.8. Cell pellets were resuspended in 200 μl of buffer containing 
50 mM Tris-HCl (pH 8.0), 200 mM NaCl, and 15 mM EDTA and incubated for 30 minutes 
138 
 
at room temperature. Samples were then transferred to a black 96-well plate (Nunclone) and 
analyzed for GFP fluorescence using an excitation filter of 485 nm, emission filter of 512 
nm, and a cutoff of 495 nm with the TECAN Infinite M200 and analyzed using Magellan v6 
software. For calculated GFP fluorescence, after subtraction of background cells-only 
fluorescence, GFP emission was normalized against the OD600 of the culture. 
 For expression of the PhoA fusion proteins, E. coli CC118 with each construct was 
grown in 1 ml LB Amp100 overnight at 37°C and then diluted 1:50 into 500 μl LB Amp100 
per well of a 48-well plate and grown at 37°C, 250 rpm to OD600=0.13-0.18. Arabinose was 
added to a final concentration of 0.2% and bacteria were grown to OD600 0.3-0.6. To prevent 
spontaneous PhoA activation, 1 mM iodoacetamide was added 10 minutes prior to harvesting 
and to all subsequent buffers. Samples were washed once in cold 10 mM Tris-HCl, pH 8.0 
containing 10 mM MgSO4 and resuspended in 1 ml cold 1 M Tris-HCl, pH 8.0. Then, 100 μl 
of each sample was added to 900 μl 1M Tris-HCl, pH 8.0 containing 1 mM ZnCl2 and an 
OD600 measurement was taken on the remaining sample. We next added 50 μl 0.1% SDS and 
50 μl chloroform, vortexed for 15 seconds, and incubated at 37°C for 5 minutes to 
permeabilize cells, then placed on ice for 5 minutes to cool. Finally, 100 μl of 0.4% p-
nitrophenyl phosphate (in 1 M Tris-HCl, pH 8.0) was added and incubated at 37°C. The 
tubes were monitored until each turned pale yellow, and then 120 μl of 1:5 0.5 M EDTA, pH 
8.0 containing 1 M KH2PO4 was added to stop the reaction. For each sample, the OD550 and 
OD420 were determined and to calculate the activity, the following equation was used: Units 
Activity= ((OD420 - (1.75 x OD550))*1000)/ (time (min) x OD600 x volume cells (ml)). 
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Protein crosslinking.  
 Overnight cultures of LVS were grown in CDM pH 6.3 and used either for 
crosslinking or re-seeded to grow to mid-log (Klett 150). Each culture was aliquoted into 
250-500 μl samples, washed once in 1X PBS, and then resuspended in the same buffer. 
Crosslinker was added to samples at a final concentration of 0.5% for formaldehyde or 0.5 
mM for dithiobis (succinimidyl propionate) (DSP). Samples were incubated at room 
temperature for 30 minutes. For DSP-treated samples, 100 mM Tris-HCl (pH 7.4) was added 
to quench the reaction. All formaldehyde-treated samples were then washed once in ice-cold 
1X PBS and resuspended in 200 μl SDS-PAGE loading buffer plus β-mercaptoethanol 
(βME) and heated at 60°C for 10 minutes (to maintain crosslinking) or at 100°C for at least 
20 minutes (to cleave crosslinking). All DSP-treated samples were resuspended in SDS-
PAGE buffer without βME (to maintain crosslinking) or with βME (to cleave crosslinking) 
and heated at 100˚C for 10 minutes. All samples were analyzed by SDS-PAGE and Western 
blotting as described below. 
 
Membrane fractionations. 
 LVS was grown overnight in 15 ml cultures in CDM pH 6.3 at 37°C, pelleted, and 
washed once in lysis buffer (150 mM NaCl, 10 mM Tris, pH 7.5). Cells were lysed in Lysis 
Matrix B tubes (MP Biomedicals) and beating in a Mini-Beadbeater (Biospec Products) for 
45 seconds twice at 4°C. Cell lysates were collected after the beads settled and clarified by 
centrifugation at 12,000 x g for 3 minutes. Crude membrane fractions were separated from 
cytoplasmic fractions by ultracentrifugation at 100,000 x g for 90 minutes, with the 
cytoplasmic fraction being in the supernatant. The remaining crude membrane fraction pellet 
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was solubilized in lysis buffer containing a final concentration of 0.5% sarkosyl and 
incubated at room temperature with shaking for 30 minutes. Insoluble outer membrane 
components were isolated from the cytoplasmic membrane fractions (supernatant) by 
centrifugation at 100,000 x g for 60 minutes (17). Protein concentrations for each fraction 
were determined using a standard BCA Assay (Thermo Scientific). 
 
SDS-PAGE and Western blotting.  
 Either 4-20% or 12% Pierce Precise™ protein gels (Thermo Scientific) were loaded 
with the designated samples at equal concentrations as determined by BCA Assay and run 
using BupH Tris-HEPES-SDS running buffer at 120 V. To determine molecular weights, 
either Benchmark™ Pre-stained Protein Ladder (Invitrogen) or PageRuler™ Plus Prestained 
Ladder (Fermentas) was used. For Western blotting, gels were transferred to nitrocellulose 
membranes at 400 mA for 45 minutes and then blocked overnight in 1% BSA in PBST. All 
antibodies were incubated at room temperature with rocking for 1 hr with PBST washes 
between incubations. Primary antibodies used were rabbit anti-RipAaa1-19 (described 
below) or mouse anti-HA monoclonal (Sigma), and secondary antibodies used were goat 
anti-rabbit IgG IRDye 680 or goat anti-mouse IgG IRDye 800CW. Protein was detected by 
near infrared fluorescence at 700 nm or 800 nm using the Odyssey Infrared Imaging System 
(LI-COR Biosciences).  
 
Generation of affinity purified antibodies against RipA peptides.  
 Two RipA peptide sequences corresponding to amino acids 1-19 and amino acids 
112-128 were synthesized by YenZyme Antibodies, LLC for the production of each peptide 
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and then rabbit antiserum and affinity purification of antibodies against each peptide. Pre-
immune sera were also collected from the rabbits and used during initial tests of the 
antibodies for reactivity and specificity in Western blots of LVS lysates.  
 
Gentamicin protection assays.  
 TC-1 epithelial cells or J774A.1 macrophages were inoculated with LVS at MOI 100 
after determining bacterial concentrations via Klett. All LVS strains were grown overnight in 
CDM pH 6.3 prior to inoculation. The cells were incubated with the bacterial inoculum for 2 
hr (J774A.1) or 4 hr (TC-1), and then incubated with media containing 25 μg ml-1 gentamicin 
for an additional 2 hr to kill the extracellular bacteria.  At 4 hr (J774A.1) or 6 hr (TC-1) and 
24 hr post infection, medium was removed, cells were washed with PBS and then scraped 
from the dish, and the bacteria serially diluted and plated to determine the number of viable 
bacteria. 
 
IL-1β ELISAs. 
 Bone marrow-derived macrophages were prepared as described above and seeded in 
12-well dishes at 1x10
6
 cells per well the same day as infection. One to two hours after 
plating, cells were then inoculated with bacteria at an MOI 500 and incubated at 37°C. After 
24 hr, the supernatants from each well were collected and centrifuged to pellet cellular 
debris.  The IL-1β ELISA was performed using the BD OptEIA mouse IL-1β ELISA kit (BD 
Biosciences) according to the manufacturer’s protocol.  The OD450 was read using a TECAN 
Infinite M200 and analyzed using Magellan v6 software.   
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Statistical analysis 
 For intracellular replication assay data, the differences for total CFU values at the 24 
hr time point for each strain was analyzed for significance using the unpaired, two-tailed 
student’s t-test. For IL-1β ELISA data, significance was determined using the repeat 
measures one-way ANOVA with a Dunnett multiple comparison post-test. Other details and 
the p-values are included in the figure legends.  All statistical values were calculated using 
GraphPad Prism v.5 software (GraphPad).   
 
RESULTS 
Mapping RipA topology of RipA using carboxyl-terminal fusion reporter proteins. 
 RipA is a 179 amino acid cytoplasmic membrane protein estimated to be 
approximately 17 kD (17). Using the annotated amino acid sequence for RipA and the 
TMHMM software (38), the topology of RipA was predicted. The data output was used in 
TMRPres2D (39) to generate the image depicted in Figure 1A. This model predicted that 
RipA has three membrane-spanning domains (amino acids 51-71, 83-103, and 152-172) with 
the amino terminus (N-terminus) in the cytoplasm and the carboxyl terminus (C-terminus) in 
the periplasm. Also predicted are two large cytoplasmic domains (amino acids 1-50 and 104-
151) and two smaller periplasmic domains within RipA (amino acids 72-82 and 173-179). It 
is rare for a protein to have only three transmembrane domains with this orientation, and very 
few such proteins have been thoroughly characterized.  
 Considering the value of validating such a unique topology for RipA, we made use of 
a fusion reporter protein system that has been used to map Escherichia coli cytoplasmic 
membrane proteins (12, 15, 33). In this system, either GFP or alkaline phosphatase (PhoA) 
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was fused at the C-terminal end of recombinant proteins or peptides, expressed in E. coli, and 
assayed for GFP fluorescence and PhoA activity. GFP is only fluorescent in the cytoplasm 
and PhoA is only active in the oxidizing environment of the periplasm (14). Thus, by fusing 
GFP and PhoA to a protein, one can determine the cytoplasmic or periplasmic location for 
the C-terminus of the protein. GFP or PhoA was fused at the C-terminus of RipA and at four 
locations predicted to be near transmembrane junctions of RipA thereby generating fusion 
proteins expressing amino acids 1-47, 1-80, 1-106, 1-148, and 1-179 (full length RipA). C-
terminal fusion proteins of DcuB and GlpT, two E. coli proteins that have been identified as 
having C-termini with periplasmic and cytoplasmic locations, respectively, were included as 
controls (12). The GFP fusion proteins were expressed in BL21 (DE3)pLysS E. coli and 
PhoA fusion proteins were expressed in phoA
-
 CC118 E. coli. GFP fluorescence or PhoA 
activity was measured for each construct, and graphed as a ratio of PhoA to GFP (Figure 1B). 
As expected, the control DcuB fusion protein had high PhoA to GFP ratio designating 
periplasmic location, and the control GlpT fusion protein had a low PhoA to GFP ratio 
designating a cytoplasmic location. In terms of RipA, fusion proteins for amino acids 1-47, 
1-106, and 1-148 had a low PhoA to GFP ratio (i.e. high GFP fluorescence) corresponding to 
a cytoplasmic location for RipA at amino acids 47, 106, and 148. Constructs for amino acids 
1-80 and 1-179 had a higher PhoA to GFP ratio (i.e. high PhoA activity) corresponding to a 
periplasmic location at amino acids 80 and 179. Thus, the fusion protein reporter system 
supports that the predicted RipA topology is correct.  
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RipA forms homoligomers as revealed by in vivo crosslinking in LVS. 
 As a small, integral cytoplasmic membrane protein, it is possible that RipA interacts 
with itself and/or other proteins. Additionally, under non-reducing conditions, higher 
molecular weight (MW) bands have been observed on Western blots probed with anti-RipA 
aa1-19 antibody. For example (Figure 2A), under non-reducing conditions (i.e. no addition of 
β-mercaptoethanol (βME)), there are at least three higher MW bands, whereas there is only 
one higher MW band in reducing conditions. This result hints that RipA may be interacting 
with itself as a homoligomer. In order to capture potential RipA oligomerization in vivo, two 
different bifunctional, reversible chemical crosslinkers, formaldehyde and DSP, were used to 
treat LVS grown in chemically-defined media. Formaldehyde was added to cells at 
concentrations ranging from 0.1-1% with the optimal percentage being 0.5%, which was 
used for subsequent experiments. Cleavage of formaldehyde-mediated protein interactions is 
accomplished by boiling samples. DSP was added to cells at concentrations ranging from 
0.5-1 mM with the optimal concentration being 0.5 mM, which was used for subsequent 
experiments. DSP-mediated interactions are reversed by the addition of βME. Crosslinking 
with either formaldehyde or DSP revealed that RipA formed 2-4 higher molecular weight 
bands of 40 kD, 55 kD, 70 kD, and sometimes 100 kD that disappear upon cleavage of the 
crosslinker (Figure 2B). These higher molecular weight bands likely represent a range of 
oligomeric states for RipA. 
 To determine whether the higher MW complexes correspond to RipA interacting with 
itself as opposed to other proteins, crosslinking experiments were performed on two 
complementary strains: HA-tagged ripA expressed on a plasmid in wild-type LVS and 
chromosomally-expressed HA-tagged ripA with wild-type ripA on a plasmid. For each strain, 
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both native and HA-tagged RipA were expressed by the ripA promoter on the same multi-
copy plasmid backbone. Each of these strains as well as wild-type LVS were crosslinked 
with formaldehyde and analyzed via Western blot using antibodies against both RipA aa1-19 
and against the HA tag. Secondary antibodies conjugated to different wavelength infrared 
dyes allowed for differential labeling of native and HA-tagged RipA (RipA-HA), and the HA 
tag allowed for differentiation by size. Due to the lower resolution of the higher MW bands, 
we focused on the ~40 kD band that corresponded to a potential RipA dimer. As expected, in 
place of a single band, there were three bands differing by only a few kD in the two strains 
containing HA-tagged and wild-type ripA. The lowest MW band corresponds to RipA/RipA 
dimers, the middle MW band to RipA/RipA-HA dimers, and the highest MW band to RipA-
HA/RipA-HA dimers (Figure 2C). These data suggest that RipA interacts with itself and 
forms a homodimer and possibly higher number homoligomers. Work to identify whether 
RipA also interacts with other proteins is underway. 
 
The cytoplasmic domains of RipA are important for RipA function. 
 Having determined the topology of RipA in the cytoplasmic membrane, we set out to 
identify which domains of RipA were required for function. Since protein-protein 
interactions often occur in the cytoplasm and because there are two large domains within 
RipA in the cytoplasm, the two cytoplasmic domains were targeted for analysis as putative 
functional domains using intracellular replication, induction of IL-1β secretion by infected 
macrophages, and RipA oligomer formation as functional read-outs. Independent deletions of 
each domain corresponding to amino acids 4-47 and 105-151 were constructed by 
replacement with a 15 amino acid linker sequence rich in glycines and serines and also two 
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prolines for flexibility. This resulted in two LVS mutants designated LVS ripA∆aa4-47 and 
LVS ripA∆aa105-151. These mutants were analyzed for intracellular replication in J774A.1 
murine macrophages (Figure 3A) and TC-1 epithelial cells (Figure 3B). The results 
demonstrate that LVS ripA∆aa4-47 and LVS ripA∆aa105-151 are both defective for 
intracellular replication in each cell type, similar to LVS∆ripA. Each mutant was also tested 
for the ability to induce IL-1β secretion as measured by ELISA on supernatants from infected 
bone marrow-derived macrophages (BMMs) (Figure 3C). Similar to what is seen for 
LVS∆ripA, LVS ripA∆aa4-47 and LVS ripA∆aa105-151 both induced increased levels of IL-
1β by infected BMMs. To validate that each protein was expressed in the proper location, 
cytoplasmic membrane fractions of each mutant were analyzed via Western blot using 
antibodies against RipA aa1-19 or RipA aa112-128 (Figure 3D). Deletion of amino acids 4-
47 and 105-151 resulted in RipA proteins that are expressed in the correct location, though at 
a slightly lower level. The apparent reduction in membrane-localized protein could contribute 
to or even account for the observed phenotypes for this mutant. Finally, to determine the role 
of each domain to the ability of RipA to oligomerize, we performed in vivo crosslinking with 
formaldehyde or DSP as described above, excluding the first deletion mutant, whose protein 
expression was too low to detect any crosslinking (Figure 3E). Unlike LVS, which again 
displayed several higher molecular weight complexes, no RipA oligomer formation was 
observed for LVS ripA∆aa105-151, suggesting that the second cytoplasmic domain is 
required for binding. Together, these data suggest that both cytoplasmic domains, 
corresponding to amino acids 4-47 and 105-151 are required for RipA function, and that at 
least the second cytoplasmic domain is required for RipA oligomerization. 
 
147 
 
At least four amino acids within RipA are required for intracellular replication and 
suppression of the pro-inflammatory response. 
 Analysis of the results from a BLASTp search using the protein sequence of RipA 
revealed a relatively short list of RipA-like proteins that have E-values below zero. 
Moreover, these proteins are found only in individual strains of a given species, which seem 
to be randomly distributed across Prokaryotes (Table S1). Thirteen amino acids are identical 
or highly conserved among the 15 RipA-like proteins with E-values less than 10
-3
. As an 
additional approach to identifying regions required for RipA function, mutants expressing 
alanine substitutions were made at each of these 13 conserved amino acids found among the 
RipA-like proteins discussed above, as well as the single cysteine, totaling 14 amino acid 
substitution mutants. Site-directed mutagenesis was performed on a plasmid containing ripA 
and the mutated plasmid was transformed into LVS∆ripA.  Each mutant was screened for 
expression of RipA in the cytoplasmic membrane using the anti-RipAaa1-19 antibody via 
Western blot on lysates of cytoplasmic membrane fractions (Figure 4A). To determine 
whether any mutant could trans-complement LVS∆ripA, each strain was analyzed for the 
ability to replicate intracellularly in J774A.1 macrophages (Figure 4B) or TC-1 epithelial 
cells (Figure 4C) and for induction of IL-1β secretion by infected BMMs (Figure 4D). The 
mutants S46A, R48A, R49A, N53A, F55A, N60A, C97A, and E134A trans-complemented 
LVS∆ripA in all assays, therefore suggesting that none of these residues are required for 
RipA function. Of the remaining mutants, W100A and P154A had variable or intermediate 
phenotypes; however, mutants Y35A, K114A, E122A and E150A did not trans-complement 
LVS∆ripA in any of the assays. Thus, at least these four respective amino acids, Y35, K114, 
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E122 and E150, are required for RipA function and corroborates with the data for the domain 
deletion mutants that both cytoplasmic domains are required for RipA function. 
 
Conservative and charge reversal amino acid changes confirm a role for K114, E122, 
and E150 in RipA function.  
 Due to their location in the second cytoplasmic domain and to further investigate the 
importance of K114, E122 and E150 to RipA function, both conservative and charge reversal 
substitutions were made at each amino acid. The substitution mutations were again generated 
using site-directed mutagenesis and the mutants assessed for intracellular replication (Figure 
5A, B) and induction of IL-1β secretion (Figure 5C). For conservative changes, E122D and 
E150D, each mutant trans-complemented the LVS∆ripA phenotype, whereas the respective 
charge reversal substitution mutants, E122R and E150R, did not. These data not only confirm 
a role of E122 and E150 in RipA function, they suggest that the charge at these sites is also 
important. For K114R, the conservative change mutant, an intermediate phenotype was 
observed, or partial trans-complementation. For K114E, the charge reversal mutant, there 
was no trans-complementation observed. Based on these data, we conclude that K114 is 
important for RipA function, but cannot determine whether the charge is responsible for its 
function. To verify that each mutant was expressed in the cytoplasmic membrane, protein 
expression was determined via membrane fractionations and Western blot using anti-
RipAaa1-19 as described above (Figure 5D). Lastly, crosslinking experiments were 
performed with K114A, E122A, and E150A to determine whether any of these amino acids 
were required for RipA oligomerization (Figure 5E, 6D). Interestingly, each mutant was still 
able to form RipA oligomers, suggesting either that these amino acids are not involved in 
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oligomerization or that there are multiple amino acids mediating the binding such that 
changing one amino acid is not sufficient to eliminate the interaction. 
 
Identification of an intragenic suppressor mutant supports a role for the first 
cytoplasmic domain in RipA function. 
 During the course of experiments with the alanine point mutants, the plasmids from 
LVS were repeatedly sequenced to verify the integrity of the ripA sequence and the desired 
mutations within RipA. In this process for K114A, E122A and E150A, we frequently 
observed mutations that resulted in a frameshift, loss of the alanine substitution mutation 
(rare), or single amino acid changes within ripA. Due to the relatively high frequency of 
mutations found within RipA-E150A, of the single amino acid changes identified, one was 
selected for further characterization, E150A with an additional V39A change, which was 
designated E150A/V39A. Assays for intracellular replication (Figures 6A, B) and also for IL-
1β secretion (Figure 6C) revealed that this mutant trans-complemented LVS∆ripA, 
suggesting that this new mutation was an intragenic suppressor. To confirm that the 
phenotype was the result of the intragenic mutation, and not the result of an extragenic 
mutation, the plasmid containing RipA E150A/V39A was isolated and re-transformed into 
LVS∆ripA three independent times. Each of these new E150A/V39A transformants was 
assayed for intracellular replication and for IL-1β secretion and displayed the same 
phenotype as the original suppressor mutant, confirming that the V39A substitution was 
responsible for trans-complementation. After formaldehyde crosslinking, the E150A/V39A 
mutant also displayed the same higher MW bands as wild-type and E150A, suggesting that 
this trans-complementation was not a result of altered oligomeric complex formation (Figure 
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6D). Of note, a mutant containing only the V39A substitution in LVS∆ripA deletion 
background did not display a defect in intracellular replication (data not shown). Overall, 
when considering the intragenic suppressor data, one can infer that the two cytoplasmic 
domains may be interacting with each other or alternatively with another protein or molecule. 
 
DISCUSSION 
 F. tularensis is a highly successful pathogen; however, many of the known virulence 
factors still have no identified function. RipA is a virulence factor that was previously shown 
to be required in vivo in a pulmonary mouse model of tularemia, likely in part due to its 
inability to suppress the pro-inflammatory response like wild-type F. tularensis LVS or Schu 
S4 (17, 22, unpublished observations). Furthermore, RipA is required for F. tularensis 
intracellular replication in both macrophages and epithelial cells (17).  However, LVS∆ripA 
escapes the phagosome with similar kinetics to wild-type F. tularensis (17). This phenotype 
suggests that a lack of RipA results in a strain unable to adapt to the environment of the host 
cell cytoplasm. Not surprisingly, LVS∆ripA grows poorly in vitro at higher pH and both ripA 
transcript and RipA protein expression are upregulated at higher pH and between 1 and 6 
hours post infection of host cells, all correlating with a role for RipA in adapting to the 
cytoplasm (16).  
 This study addresses the question of RipA function at the biochemical and molecular 
level. Preceding studies demonstrated that RipA localizes to the cytoplasmic membrane of F. 
tularensis (17). Here, the topology of RipA within the cytoplasmic membrane was 
determined in terms of orientation and subcellular location of functional domains. RipA has 
three transmembrane domains, two large cytoplasmic domains and two smaller periplasmic 
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domains with the N-terminus in the cytoplasm and the C-terminus in the periplasm. 
Additionally, RipA was shown to form homoligomers in the membrane using in vivo 
crosslinking with either formaldehyde or DSP, and even in the absence of protein 
crosslinkers, the protein can exist in higher order forms. The first of several higher MW 
bands appears to correspond to at least a dimer size (~40 kD), suggesting that RipA forms a 
homodimer. RipA homodimerization was confirmed by the experiments using strains 
expressing both RipA and RipA-HA where in place of the single 40 kD band there were 3 
bands corresponding to RipA-RipA dimers, RipA/RipA-HA dimers and RipA-HA/RipA-HA 
dimers. Due to the lack of resolution for the higher bands in these experiments and since 
these bands are not exactly trimer, tetramer, etc. in size, we cannot definitively say whether 
or not these bands are solely RipA or RipA crosslinked to another protein; however, based on 
the characteristic banding pattern, we suspect that these forms represent homoligomers as 
well. We are in the process of determining whether or not RipA interacts with any other F. 
tularensis proteins. Further insight into RipA topology, structure, and ultimately function, 
could be gained through biochemical experiments such as size exclusion chromatography 
and solving the crystal structure. 
 Francisella RipA proteins and some of the other RipA-like proteins have only a 
single cysteine found in the second transmembrane domain, which is uncommon. The highly 
reactive thiol group of a cysteine is known to be involved in several biological functions, 
most prominently the formation of disulfide bonds with other cysteine residues. These 
disulfide bonds can occur within the same protein to maintain tertiary structure or with a 
cysteine from another protein to mediate intermolecular complex formation, making unpaired 
cysteines quite rare. Due to the high reactivity of the thiol group, cysteine is not usually 
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found in isolation, and proteins with a single cysteine form oligomers or bind metals or other 
molecules via this amino acid. The fact that the RipA C97A mutant still formed oligomers 
(data not shown), was not attenuated for intracellular growth, and did not induce IL-1β 
secretion by infected macrophages suggests that this is not the case for RipA. Thus, the role 
of this single cysteine in RipA function remains unknown. One explanation is that there is no 
specific role for C97 in RipA function, especially considering that the cysteine is not 
completely conserved in all RipA-like proteins and that in some RipA-like proteins there is 
more than one cysteine present. Alternatively, the cysteine has a function unique to only 
Francisella RipA or a subset of RipA-like proteins. An interesting possibility is that the 
cysteine is involved in conformational changes of the RipA protein or binds to a small 
molecule as opposed to directly binding to protein partners.  
 Employing the topology model of RipA, we targeted specific domains for assessment 
of their role in RipA function. Using domain deletion mutants we found that each 
cytoplasmic domain was required for RipA function in terms of intracellular replication in 
macrophages and epithelial cells and suppression of the pro-inflammatory immune response 
and that at least the second cytoplasmic domain was required for RipA oligomer formation. 
This is further supported by analysis of the Y35, K114, E122, and E150 substitution mutants, 
each of which is within the cytoplasmic domains, and showed that these amino acids were 
also required for intracellular replication in both macrophages and epithelial cells as well as 
for suppression of the pro-inflammatory immune response. Unlike the RipA ∆aa105-151 
cytoplasmic domain deletion mutant, the single amino acid changes were not sufficient to 
prevent RipA oligomerization, suggesting that the interactions are mediated by multiple 
amino acids or that the individual amino acids are involved in some other aspect of RipA 
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function.  In terms of the first cytoplasmic domain, the inability to determine the involvement 
of aa4-47 to RipA oligomer formation was due to RipA∆aa4-47 decreased cytoplasmic 
membrane expression. Nevertheless, there is a possibility that the first cytoplasmic domain is 
involved in formation of RipA oligomers and even that the two cytoplasmic domains interact. 
The intragenic suppressor mutation V39A in the E150A mutant restores the ability of the 
E150A mutant to replicate intracellularly and suppress the IL-1β response. Considering that 
V39 and E150 are in the first and second cytoplasmic domain, respectively, suggests that the 
two cytoplasmic domains interact with each other or alternatively with another shared 
substrate. Overall, our data show that both cytoplasmic domains, and even certain amino 
acids within each domain are important for RipA function. 
 The fact that there are other RipA-like proteins in a wide range of mainly less-studied 
species, including pathogenic, non-pathogenic, Gram-positive, Gram-negative, 
Mycobacteria, soil-dwelling, marine-dwelling, freshwater-dwelling and even one Archaea 
member is intriguing. Stranger still is that there have only been RipA proteins identified in 
select strains of a given species with the exception being Francisella, in which RipA is 
conserved among all sequenced species and strains. This could be due in part to a lack of 
genome sequences for a given species, or RipA could truly be a rare protein, or one for which 
there are functional homologs that share little protein sequence homology. So far RipA-like 
proteins have been identified in only four strains of pathogenic bacterial species: 
Mycobacterium avium, which can cause disease in birds as well as children, elderly and the 
immune-compromised, Streptomyces scabiei, which causes disease in plants, and Aeromonas 
caviae, which is a cause of gastrointestinal disease in humans, and Actinomyces 
odontolyticus, which is an opportunistic pathogen causing invasive disease in elderly or 
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immune-compromised patients with advanced dental cavities. Whether or not these RipA-
like proteins play a role in pathogenesis is not known. Since we know that RipA is an 
important virulence factor for F. tularensis, it is possible that the function of RipA will 
represent a conserved virulence mechanism among pathogenic bacteria. Alternatively, and 
equally exciting would be that RipA functions as a novel virulence mechanism unique to 
Francisella. Being that the bacteria in which other RipA-like proteins are found are so varied 
in classification, it will be interesting to determine if there are differences in function of RipA 
among the pathogenic and non-pathogenic strains. The fact that a virulence gene homolog is 
found in environmental bacteria is not unfounded. A recent in silico analysis of marine 
bacteria genomes for virulence factors revealed that there was an abundance of well-
characterized virulence genes, including pathogenicity islands and genes encoding secretion 
systems and toxins, represented among the analyzed strains (32). Genes encoding virulence 
factors are also widely distributed among soil bacteria as well (4). Perhaps RipA belongs to a 
novel family of proteins that will be revealed as more strains are sequenced and deposited 
into NCBI resulting in more RipA-like proteins being identified. Overall, determining the 
function of RipA is relevant not only for understanding the virulence of F. tularensis, but 
also perhaps for understanding the function of a potential class of proteins distributed 
throughout the Prokaryotes. 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Mapping of RipA within the cytoplasmic membrane using C-terminal fusion 
reporter proteins in Escherichia coli. (A) The predicted topology model for RipA was 
determined using TMHMM and the image made using TMRPres2D. The yellow tags label 
the 13 amino acids that are conserved among RipA-like proteins in other bacterial strains as 
well as the single cysteine found within Francisella RipA. The colors designate electrostatic 
potential with red highlighting negatively-charged amino acids and blue highlighting 
positively-charged amino acids. (B) RipA C-terminal fusion proteins were expressed in E. 
coli alongside GlpT and DcuB C-terminal fusion proteins as GFP and PhoA positive 
controls, respectively. Each strain was assayed for PhoA activity or GFP fluorescence as 
appropriate. Data are represented as PhoA to GFP ratio consolidated from at least three 
experiments for each construct performed in triplicate. Error bars represent the standard 
deviation of the PhoA to GFP ratio values composite from all experiments. 
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Figure 2. In vivo protein crosslinking of RipA.  (A) Western blot of LVS lysates probed 
with anti-RipAaa1-19 after SDS-PAGE under non-reducing conditions (no βME) in Lane 1 
and under reducing conditions in Lane 2. (B) LVS treatment either with 0.5 mM DSP or 
0.5% formaldehyde (Form.) and analyzed by Western blot using anti-RipAaa1-19. 
Incubation of samples at 100°C (formaldehyde) or addition of βME (DSP) cleaved selected 
samples as designated. (C) LVS (Lanes 1-3), LVS with plasmid-expressed RipA-HA (Lanes 
4-6), and LVS with chromosomally-expressed RipA-HA plus plasmid-expressed wild-type 
RipA (Lanes 7-9) were grown overnight and incubated with 0.5% formaldehyde and 
analyzed by Western blot probed with anti-RipAaa1-19 (red) and anti-HA (green). Lane 1, 4, 
7- untreated; Lanes 2, 6, 8- 0.5% formaldehyde; Lanes 3, 7, 9- 0.5% formaldehyde plus 
100°C. The images below each panel of the Western blot are cropped and enlarged from the 
Western blot to focus on the bands of interest. Although from the same blot, the panel 
containing lanes 7-9 was exposed at a lower intensity in the red channel in order to 
distinguish the fainter upper band (green channel) and this results in the upper band 
appearing more green than the expected yellow as seen in lanes 4-6. All data shown are 
representative of at least three experiments. 
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Figure 3. Characterization of two RipA cytoplasmic domain deletion mutants. (A) 
Intracellular replication of wild-type LVS, LVS∆ripA, LVS ripA∆aa4-47, and LVS 
ripA∆aa105-151 was assessed within J774A.1 macrophages (A) and within TC-1 epithelial 
cells (B) as determined by gentamicin protection assay. Each graph is representative of one 
of three experiments each performed in triplicate, and the error bars signify standard 
deviation between triplicates. (C) Secretion of IL-1β by BMMs at 24 hr as measured by 
ELISA on supernatants of cells left untreated or incubated with LVS, LVS∆ripA, LVS 
ripA∆aa4-47, or LVS ripA∆aa105-151. The graph represents the results from one of at least 
three experiments performed in triplicate with error bars representing the standard deviation 
between replicates. (D) Protein expression of LVS, LVS∆ripA, LVS ripA∆aa4-47, and LVS 
ripA∆aa105-151 in LVS cytoplasmic membrane fractions was determined by Western blot 
probed with anti-RipAaa1-19. (E) In vivo crosslinking on wild-type LVS (lanes 1-5) and 
LVS ripA∆aa105-151 (lanes 5-10) was performed by treatment with 0.5% formaldehyde or 
0.5 mM DSP. For some samples, cleavage was achieved by addition of βME (DSP) or 
incubation at 100°C (formaldehyde) as designated. Crosslinking was followed by Western 
blot analysis probed with anti-RipAaa1-19. The Western blots shown are representative of at 
least three experiments. Statistical significance was determined by comparing the values for 
each respective mutant to the values for LVS∆ripA. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure 4. Characterization of RipA alanine substitution mutants RipA for intracellular 
replication and suppression of the pro-inflammatory response. (A) The 14 RipA alanine 
substitution mutants were expressed in LVS∆ripA and analyzed for protein expression in the 
cytoplasmic membrane fractions of LVS by Western blot probed with anti-RipAaa1-19. Each 
mutant was assessed for intracellular replication in J774A.1 macrophages (B) and TC-1 
epithelial cells (C) as measured by gentamicin protection assay. The graphs represent a 
consolidation of data for each mutant from a representative of at least two experiments 
performed in triplicate with the error bars signify standard deviation between triplicates. (D) 
Each mutant was analyzed for induction of IL-1β secretion by infected BMMs at 24 hr as 
measured by ELISA. The graph represents a consolidation of data for each mutant from a 
representative of at least two experiments performed in duplicate or triplicate, and the error 
bars signify standard deviation between replicates. Statistical significance was determined by 
comparing the values for each respective mutant to the values for LVS∆ripA + ripA since this 
strain has the backbone plasmid on which the mutants were made. *, p < 0.05; ***, p < 
0.001. 
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Figure 5. Further analysis of amino acids K114, E122 and E150 to RipA function. The 
charge reversal and conservative amino acid substitution mutants for K114, E122, and E150 
were assessed for intracellular replication within J774A.1 macrophages (A) and within TC-1 
cells (B) using gentamicin protection assays. The graphs represent a consolidation of data for 
each mutant from a representative of at least two experiments performed in triplicate, and the 
error bars signify standard deviation between triplicates. (C) Each mutant was analyzed for 
induction of IL-1β secretion by BMMs at 24 hr as measured by ELISA on supernatants of 
infected cells. The graph represents a consolidation of data for each mutant from a 
representative of at least two experiments performed in duplicate or triplicate, and the error 
bars signify standard deviation between replicates. (D) Each mutant was assessed for protein 
expression in the cytoplasmic membrane fraction of LVS by Western blot analysis probed 
with anti-RipAaa1-19. (E) Wild-type LVS and the K114A and E122A mutants were 
crosslinked with 0.5% formaldehyde and analyzed by Western blot probed with anti-
RipAaa1-19. Statistical significance was determined by comparing values for each respective 
mutant to the values for LVS∆ripA + ripA. **, p < 0.01; ***, p < 0.001. 
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Figure 6. Identification and characterization of an intragenic suppressor mutation in 
RipA E150A. A spontaneous V39A suppressor mutation appeared in the E150A mutant 
(E150A/V39A), and this plasmid was used to re-transform three LVS∆ripA strains and 
generate E150A/V39A-R1, R2, R3. Wild-type LVS, LVS∆ripA, LVS∆ripA + ripA, the 
E150A mutant, E150A/V39A, and E150A/V39AR1-3 were assessed for intracellular 
replication within J774A.1 macrophages (A) and within TC-1 epithelial cells (B) as 
determined by gentamicin protection assay. The graphs represent a consolidation of data for 
each mutant from a representative of at least two experiments performed in triplicate with the 
error bars signify standard deviation between triplicates. (C) Secretion of IL-1β by 
macrophages at 24 hr as measured by ELISA on supernatants of infected cells. The graph 
shows a representative of at least two experiments performed in duplicate or triplicate, and 
the error bars signify standard deviation between replicates. (D) Wild-type LVS, the E150A 
mutant, and the E150A/V39A mutant were crosslinked using 0.5% formaldehyde and 
analyzed by Western blot probed with anti-RipAaa1-19. The Western blot shown is 
representative of at least two experiments. Statistical significance was determined by 
comparing the values for each respective mutant to the values for LVS∆ripA + ripA. *, p < 
0.05; **, p < 0.01; ***, p < 0.001. 
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Bacterial Strain Accession # E-value Description of strain/species 
Acidovorax 
delafieldii 2AN 
Alicycliphilus 
denitrificans K601  
ZP_04761593.1 
YP_004388625 
 2x10
-14
 
Gram-negative, β-Proteobacteria, 
aerobic, water-dwelling  
Gram-negative, β-Proteobacteria, 
aerobic, de-nitrifying, breaks 
down cholates, soil 
Thermomonospora 
curvata DSM43183  
YP_003299058.
1 4x10
-14
 
Gram-positive, Actinobacteria, 
aerobic, cellulolytic thermophile, 
isolated from straw compost 
Hylemonella gracilis 
ATCC 19624  
ZP_08407204.1 
1x10
-13
 
Gram-negative, β-Proteobacteria, 
aerobic, spirillum-shaped, 
isolated from pond water, 
stagnant or still freshwater  
Streptomyces 
lividans TK24  
ZP_05525530.1 
2x10
-13
 
Gram-positive, Actinobacteria, 
aerobic, producer of small 
molecule natural products 
Streptomyces 
cattleya NRRL 8057 
CCB74526.1 
4x10
-13
 
Gram-positive, Actinobacteria, 
aerobic, fluorinase producer 
Aeromonas caviae 
Ae398  
ZP_08522295.1 
4x10
-13
 
Gram-negative, γ-Proteobacteria,  
facultative anaerobe, cause of 
gastrointestinal diseases 
Streptomyces 
coelicolor A3(2)  
NP_627504.1 
2x10
-12
 
Gram-positive, Actinobacteria, 
aerobic, soil-dwelling, lifecycle 
involving mycelial growth and 
spore formation 
Beggiatoa sp. PS  ZP_02000104.1 
4x10
-12
 
Gram-negative,  γ-
Proteobacteria, aerobic, 
filamentous, marine 
environment, chemosynthesizer, 
isolated originally from the 
German coast of the Baltic Sea, 
one of the largest Prokaryotes 
Nocardioidaceae 
bacterium Broad-1  
ZP_08194929.1 
2x10
-11
 
Gram-positive, Actinobacteria, 
contaminant during the assembly 
of Coccidioides genomes 
Moritella sp. PE36  ZP_01896445.1 
3x10
-11
 
Gram-negative, γ-Proteobacteria, 
aerobic, deep-sea piezophile 
heterotroph, adapted to high 
pressure, cryophilic 
Streptomyces scabiei  
87.22  
YP_003490655.
1 
4x10
-10
 
Gram-positive, Actinobacteria, 
aerobic, mesophilic, motile, soil-
dwelling, causes scab diseases
 
of 
potatoes and other root crops 
Mycobacterium 
avium subsp. avium 
ATCC 25291  
ZP_05215248.1 
3x10
-8
 
Mycobacteria/Gram-positive, 
Actinobacteria, aerobic,  
mesophilic, isolated from the 
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Table 4.1  List of bacterial strains (other than those belonging to the Francisella genus) that 
have a RipA-like protein, as identified by BLASTp to Francisella RipA at the time of 
manuscript submission. Descriptive information was obtained from NCBI. 
  
liver of a hen and causes disease 
in birds as well as children, 
elderly and immune-
compromised 
Desulfobacterium 
autotrophicum 
HRM2  
YP_002602733.
1 
4x10
-8
 
Gram-negative, δ-Proteobacteria, 
anaerobic, mesophilic, found in 
marine sediments, sulfate-
reducing, isolated from 
Mediterranean Sea 
Actinomyces 
odontolyticus F0309  
ZP_06609016.1 
1x10
-6
 
Gram-positive, Actinobacteria, 
aerobic, mesophilic, non-motile  
oral bacterium isolated from 
dental caries, can cause systemic 
disease in elderly and immune-
compromised humans with 
advanced dental cavities 
Archaeoglobus 
profundus DSM 
5631  
YP_003401486.
1 
3x10
-6
 
Archaea,  Euryarchaeota, 
anaerobic, hyperthermophilic, 
motile, isolated from a deep sea 
hydrothermal vent,  
Actinomyces sp. oral 
taxon 178 str. F0338  
ZP_08026401.1 
1x10
-5
 
Gram-positive, Actinobacteria, 
oral bacterium 
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SUMMARY AND FUTURE DIRECTIONS 
 F. tularensis has a low infectious dose and causes the potentially fatal disease 
tularemia, but despite the knowledge of F. tularensis being such a successful pathogen, not 
much is known about its mechanisms of virulence. Part of the struggle to understanding F. 
tularensis virulence is the seeming lack of typical virulence factors employed by other 
pathogenic bacteria such as toxins or the Type III, IV, or V secretion systems. In fact, 
approximately 30% of the F. tularensis genome encodes hypothetical proteins, many of 
which have little or no homology to other characterized proteins (16). Another factor 
contributing to the relative lack of knowledge on F. tularensis virulence mechanisms is that 
only recently have the necessary genetic tools become available. Within the last decade, as 
these means have been utilized, numerous screens have been performed and through which, a 
significant number of proteins that contribute to F. tularensis pathogenesis were revealed  (1-
3, 14, 15, 18, 21, 24-26, 29, 31). Nonetheless, many of the studies remain descriptive in 
nature, and therefore, the functions of the majority of these virulence factors remain 
unknown. 
 In a search for proteins that were required for intracellular replication within the host 
lung epithelial cell, our lab identified the locus FTL_1914, which we called ripA (required 
for intracellular proliferation factor A). Deletion of ripA in LVS resulted in a mutant 
(LVS∆ripA) that was defective for intracellular replication in both epithelial cells and 
macrophages (12). Interestingly, unlike many of the previously described mutants, 
LVS∆ripA escapes the phagosome with the same kinetics as wild-type LVS, and therefore, 
the decreased replication is not the result of an inability to escape the phagosome (12). 
Furthermore, at later time points post-infection, like wild-type LVS, LVS∆ripA is reported to 
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re-enter the FCV (12). Deletion of ripA in the highly virulent Schu S4 strain (Schu S4∆ripA), 
results in a mutant that is defective for intracellular replication as well (our unpublished 
results, Dr. Sharon Taft-Benz). In addition, both ripA gene expression and RipA protein 
expression are upregulated at a higher pH and within macrophages during the first several 
hours of infection, and LVS∆ripA grows poorly in broth media cultures at a high pH (13). All 
of this data suggest LVS∆ripA is unable to adapt to the host cytoplasmic environment, 
although the specific reasons are not clear. 
 Further evidence to a role for RipA to F. tularensis virulence was shown through the 
studies described in chapter 3, in which we demonstrated the inability of LVS∆ripA and Schu 
S4∆ripA to suppress the pro-inflammatory immune response. Using PFA-killed LVS and 
LVS∆ripA, we found that the suppression of the immune response is an active process, i.e. 
the reason for the increased LVS∆ripA-mediated immune induction cannot be only due to 
gross morphological changes in the bacterial cell surface or to a cell surface protein that is 
present in LVS∆ripA regardless of bacterial viability. Moreover, mixed infections with LVS 
and LVS∆ripA, led to a loss in IL-1β induction, suggesting that the presence of wild-type 
bacteria can suppress the immune response induced by LVS∆ripA (our unpublished results). 
Active suppression of the immune response by wild-type F. tularensis is further supported by 
other studies (5-7, 9, 17, 27, 28). 
 Since RipA is an inner membrane protein, it is probable that the effects on the 
immune response are indirect and that RipA does not directly interfere with or bind to host 
immune receptors. RipA could either be interacting with other proteins that interfere with the 
pro-inflammatory signaling pathways or alternatively, the loss of RipA be altering the 
bacterial membrane in such a way to expose other immune-interacting proteins or molecules, 
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in a manner that requires viable bacteria. Additional studies in our lab also indicate that the 
outer membrane, LPS, and lipid A profiles of LVS∆ripA are unchanged and that LVS∆ripA 
LPS does not stimulate IL-1β or TNF-α secretion by infected macrophages (our unpublished 
results, Cheryl N. Miller). Therefore, further studies are needed to determine if a more subtle 
or specific change is the source of the enhanced induction of the pro-inflammatory response 
in the absence of ripA. Significantly, these studies helped to provide further insight into the 
pathways that are being suppressed by wild-type F. tularensis, most notably the role for the 
MAP kinases ERK1/2, JNK, and p38. Future studies will include further dissection of the 
signaling pathways targeted by F. tularensis and activated by LVS∆ripA with a priority on 
the identification of cytoplasmic sensors upstream of inflammasome activation. Identification 
of the protein that is responsible for sensing LVS∆ripA, as well as other specific downstream 
pathways and proteins, could be useful in determining RipA function. In general, 
understanding the mechanisms by which F. tularensis modulates the host response to 
infection is principal in prophylactic and vaccine development not only in accounting for 
host responses but also for identification of bacterial drug targets. 
 For a small inner membrane protein of 17 kD, RipA has an unusual topology. More 
specifically, with a large cytoplasmic N-terminus, two transmembrane alpha-helices linked 
by a short periplasmic domain, a second large cytoplasmic domain, a third transmembrane 
domain, and a short periplasmic C-terminus. What’s more, RipA contains only a single 
cysteine residue found within the second transmembrane domain. Cysteines contain a highly 
reactive thiol group that is usually involved in forming intramolecular disulfide bonds and 
occasionally binding to metals or other molecules. This reactivity makes unpaired cysteines 
quite rare; however, such cases often involve the cysteine binding to a cysteine from another 
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protein to mediate an intermolecular complex formation. With this in mind, we tested RipA 
for the ability to form oligomers using crosslinking agents, formaldehyde and DSP, and 
through this we learned that RipA forms homodimers. The characteristic banding pattern 
observed when crosslinking RipA suggests that RipA may be forming trimers, tetramers, and 
pentamers as well. Surprisingly, the cysteine in RipA was not required for oligomer 
formation nor for F. tularensis intracellular replication or suppression of IL-1β, so the role of 
RipA’s single cysteine remains unknown.  
 Nevertheless, further experiments are required to clarify whether these higher MW 
complexes represent homo-oligomers and/or RipA interacting with another protein(s). Mass 
spectrophotometry on crosslinked RipA complexes as well as size exclusion chromatography 
on RipA-containing inner membrane fractions are currently being performed in pursuit of 
further defining the composition of RipA complexes. Localization studies using electron 
microscopy or immunofluorescence would also be useful in determining the distribution of 
RipA within the inner membrane of the bacterium. Future experiments also include further 
characterization of the role of various amino acids and domains to RipA function. We have 
already established that the two cytoplasmic domains are required for virulence and RipA 
oligomer formation. We would like to address the possibility that these two domains interact, 
for example, by FRET, yeast two-hybrid, or immunoprecipitation. By targeting additional 
amino acids or groups of amino acids by mutagenesis we can hope to narrow down regions 
of RipA that are mediating oligomerization and potentially binding to other proteins. Finally, 
as discussed in chapter 1, RipA was identified in a screen looking for glycosylated proteins, 
so we also plan to determine whether or not RipA is glycosylated at a predicted glycosylation 
site within the N-terminal cytoplasmic domain (4). Overall, additional biochemical 
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experiments will be beneficial to understanding RipA topology, oligomer formation, and 
eventually, RipA function. 
 Since RipA has two large cytoplasmic domains, RipA likely interacts with 
cytoplasmic proteins. The search for RipA-interacting proteins was initiated by means of 
immunoprecipitation using HA-tagged RipA and LVS lysates (11). These studies revealed a 
list of putative RipA-interacting proteins, one of which was confirmed using reciprocal pull-
down experiments. This RipA-interacting protein (FTL_1364) had significant homology to 
proteins within the IclR family of transcriptional regulators, and therefore, we named this 
protein IclR. The homologous locus in F. novicida (FTN_0720) had previously been 
described as being required in vivo in the mouse after subcutaneous or intraperitoneal 
inoculation, for suppression of the pro-inflammatory response and cytotoxicity (31). 
Interestingly, the novicida iclR mutant was still able to replicate intracellularly in 
macrophages (31). Despite this, the other data in the study suggested that IclR contributes to 
virulence, and that its role may be at least in part through its interactions with RipA.  
 Therefore, we deleted the gene encoding IclR in the more highly pathogenic LVS 
(FTL_1364) and in Schu S4 (FTT_0748), and analyzed these mutants for intracellular 
replication, ability to induce IL-1β secretion and cytotoxicity in infected macrophages, and in 
vivo in the mouse following intranasal or intradermal inoculation. Surprisingly, all of the iclR 
deletion mutants behaved like wild-type strains in all assays; however, our examination of a 
F. novicida iclR transposon mutant confirmed the previously published results that iclR is 
required for F. novicida virulence in vivo. Microarray studies and subsequent synteny 
analysis of the results show that loss of IclR results in expression changes in genes that are 
disrupted in LVS and Schu S4, but not in F. novicida U112. These data suggest that in spite 
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of the changes in gene expression in all of the iclR mutants, the loss or disruption of affected 
genes in LVS and Schu S4 may at least partially account for why iclR is not required for 
virulence in these virulent strains. The precedence for this conclusion is also supported by the 
fact that the tularensis and holarctica species are noted for their genome decay. For example, 
both tularensis and holarctica genomes have a few hundred pseudogenes, while the F. 
novicida U112 genome has only fourteen (16, 30).  The tularensis and holarctica genomes 
are also distinguished from the U112 genome in the increased presence of transposase 
sequences and gene rearrangements (16, 23, 30). Therefore, it’s possible that IclR affects a 
similar set of genes shared among the species of Francisella, but due to the genome decay in 
the virulent strains, many of the transcripts are unable to be translated into functional 
proteins. Moreover, as discussed in chapters 1 and 2, the acid phosphatases AcpABC are 
required for the virulence of U112, but not for Schu S4 (10, 19, 20). Overall, combined with 
the different pathogenicity of each species for humans, these studies highlight differences 
between the Francisella species.  
 Even though IclR does not appear to be required for virulence of F. tularensis, the 
fact that expression of limited numbers of transcripts were significantly changed between 
LVS wild-type and ΔiclR strains suggest that IclR may in fact be a transcriptional regulator. 
Future studies with IclR include characterizing IclR as a transcriptional regulator by means 
of DNA binding assays, mutagenesis, and more detailed transcriptional studies in novicida. 
We would like to investigate further the microarray-identified genes to help us gain further 
insight into the function of IclR in Francisella. It is possible that IclR still plays an important 
role for Francisella survival in the environment or other hosts. Finally, we plan to further 
investigate the IclR-RipA interaction and whether or not this interaction is biologically 
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relevant. To do this, we would need to first validate the in vitro interaction with other assays, 
e.g. microscopy, FRET, or the crosslinking with mass spectrophotometry studies mentioned 
above, as a true interaction could provide insight into RipA function. Preliminary studies 
suggest that there is no overlap in gene expression changes identified by microarray for 
LVSΔiclR compared to LVSΔripA, which goes against the hypothesis that the IclR-RipA 
interaction is related to the putative transcriptional activity of IclR. 
 The original immunoprecipitation studies with RipA identified multiple putative 
RipA-interactors, so there are more proteins that we can investigate that may help elucidate 
RipA function. One promising contender is the protein LpxA, which we have since 
confirmed the interaction with RipA using reciprocal pull-downs with tagged proteins (our 
unpublished results, Cheryl N. Miller). Spontaneous extragenic suppressor mutations of 
LVS∆ripA were also identified within lpxA and glmU, both genes involved in lipid A 
biosynthesis, which complemented the LVS∆ripA intracellular growth defect (our 
unpublished results, Cheryl N. Miller). These data suggest that RipA may be involved in LPS 
biosynthesis and/or membrane biogenesis. Studies looking at membrane permeability suggest 
that there are only mild differences between LVS and LVS∆ripA susceptibility to antibiotics 
and other compounds, and more detailed studies exploring this phenotype are underway (our 
unpublished results, James R. Fuller, Cheryl N. Miller and myself). Changes to the 
membrane also would correspond with the LVS∆ripA inability to suppress the immune 
response as such changes could uncover epitopes that could be recognized by the host, 
although other mechanisms could account for the lack of immune suppression by LVS∆ripA. 
 The ripA gene is conserved among the species of Francisella, suggesting that the 
RipA protein functions the same among Francisella. To substantiate this observation, we 
179 
 
have also found that plasmid-expressed F. novicida ripA can functionally complement 
LVS∆ripA for intracellular replication in both macrophages and epithelial cells as well as for 
suppression of the IL-1β secretion by infected cells (our unpublished results). While we have 
not investigated the role of ripA to virulence in F. novicida, we expect that based on the 
above data and gene conservation, that ripA is also required for the virulence of F. novicida 
as well as other pathogenic species of Francisella. Alignments of the genomic regions that 
immediately surround ripA show that there are some sequence differences in the 5’ and 3’ 
regions among the three strains, most notably in U112. Therefore, it’s possible that the 
differences in this region could result in differences in the role of RipA to the virulence of F. 
novicida, and future studies could include investigation into these differences.  
 Along those lines, we have observed that there are other RipA-like proteins in strains 
of several Prokaryotic species. The fact that there are RipA-like proteins in such a randomly-
distributed group of Prokaryotes, including mainly non-pathogens, is intriguing. As discussed 
in chapter 4, to date there are only four pathogenic bacteria known have a RipA-like protein, 
and whether or not these RipA-like proteins play a role in pathogenesis is not known. There 
is the possibility that RipA is a conserved virulence protein, but on the other hand, RipA may 
function as a novel virulence factor unique to Francisella. Future studies could include 
investigating whether the loss of the RipA-like protein in these organisms result in decreased 
virulence, and if so, whether F. tularensis RipA can complement the observed attenuated 
phenotype. It will also be worthwhile to establish if there are differences in RipA function 
among the pathogenic and non-pathogenic organisms, as many non-pathogenic bacteria 
encode virulence factors in their genomes (8, 22). It is exciting to speculate that RipA 
belongs to a novel family of proteins. To that end, future experiments could include 
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complementation studies in which RipA-like proteins from other Prokaryotes are expressed 
in F. tularensis ripA deletion mutants to see if they complement the deletion mutant 
phenotypes. Though the current list is small, as more strains are sequenced and deposited into 
public databases, more RipA-like proteins may be identified that will contribute to our 
determining RipA function. In the end, determining the function of RipA will not only help 
understand the function of perhaps a widely-distributed, larger class of proteins, but also 
bring a better understanding of the virulence of the highly-infectious and successful pathogen 
F. tularensis. 
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